Fortune.com - Even the type of sequencing done in the U.S. has been lacking, some experts say, with much of the effort focused on finding cases of the U.K. variant, rather than casting a wider net for any variant, including ones not previously identified, said Jeremy Kamil, a virologist at Louisiana State University Health Shreveport.

KTBS 3 - “We have a very robust surveillance, viral sequencing surveillance program in place,” Dr. Chris Kevil said. "Viral sequencing tracks the movement of the virus lineages or where it has spread across the country. The center has been able to identify the strain unique to the North Louisiana area and has tracked it as others have taken it to other parts of the country."

KTBS-3 - The Center of Excellence for Emerging Viral Threats at LSU Health Shreveport plays a big role in COVID-19 testing and community vaccinations. But another important role it plays involves the identification of COVID-19 mutations and the variants they cause.

KSLA 12- “If the EVT Lab had not existed, quite frankly, I think we’d be in a much darker place here in the northern part of the state,” said Dr. Chris Kevil, vice chancellor of research and one of the leading minds behind creation of the lab. “The EVT Lab has been fundamental in our ability to monitor COVID infections in patients out in this community."

KTBS 3 - Andrew Yurochko, Professor of Microbiology and Immunology at LSUHS, shares, “When you think about total tests, 0.1% of the total tests of the entire country are done right here in Northwest Louisiana, where we’ve focused on our own citizens, not just in Shreveport or Caddo Parish, but in all of Region 7 which is Northwest Louisiana.”

The Emerging Viral Threat Lab at LSU Health Shreveport has processed over 110,000 COVID-19 test samples from multiple public health regions of the state and created over 170,000 test kits which were distributed throughout the state during its first six months of operation.

Health Matters host, Dr. Sanford Katz, was  joined by LSUHS's Andrew Yurochko, PhD, Professor of Microbiology and Immunology and Carroll Feist Chair of Viral Oncology and Dr. John Vanchiere, Chief of the Department of Pediatrics Infectious Diseases. to discuss testing, treatments and vaccines for COVID-19.

The Daily Beast - "Louisiana is getting pummeled by the virus. But without a comprehensive early testing program in Shreveport, it would have been worse still."

Shreveport Times - From the formulation of an emerging viral threat lab to community testing, LSU Health Shreveport has actively fought COVID-19. Dr. Chris Kevil talks about testing, clinical trials and prevention.

LSU Health Shreveport has established the Emerging Viral Threat (EVT) Laboratory to address the need for faster detection and processing of COVID-19 tests.

“We are excited to be approved for this early intervention treatment aimed at stopping the progression of the virus which gives patients an improved chance of recovering quickly by preventing the virus from worsening. This treatment will be especially important should we see an increase in the number of COVID-19 positive patients," Dr. Keith Scott said.

KTBS 3 - "We will confirm that they can detect the novel coronavirus, and then we will determine the amount. And we provide that information back to LifeShare Blood Center so that LifeShare can then make decisions about which plasma they will send out when requested by hospitals," Dr. Matthew Woolard said.

Keith Scott, MD, MSc, FCCM, Professor and the clinical trial's Principal Investigator for the nitric oxide trials at LSU Health Shreveport says, "Teasing out the influence of naturally produced NO on this process is difficult. What I am very encouraged about is the demonstration of virus in the endothelial cells of the lung tissue."

Combining his experience not only as a principal investigator on numerous clinical trials but also as a critical care physician for over thirty years, Dr. Scott will provide medical support and oversight for all clinical trials conducted at LSU Health Shreveport.

KTBS 3 - LSU Health Shreveport announced this week that it is participating in the Pfizer COVID-19 vaccine study and is currently enrolling people to participate.

LSUHS is expanding enrollment in the Pfizer-sponsored COVID-19 vaccine study for the next two weeks to include individuals ages 16-18 and those older than 85 years of age.  Those interested in participating in this important vaccine trial should sign up as quickly as possible.  

Phase two in the fight against COVID-19 is ramping up. The fight began with testing, now it's the race to find a treatment and eventually a vaccine. Convalescent plasma is so far showing great promise.

Officials say a critically ill COVID-19 patient at Ochsner LSU Health Shreveport Academic Medical Center is being treated with the first convalescent plasma therapy in Louisiana, donated at LifeShare Blood Center just hours before the treatment began Saturday.

The FDA just released new guidelines allowing us to investigationally use convalescent plasma for patients with moderate to severe COVID-19 infections.  The only source of this convalescent plasma is donations from people that have recovered for at least two weeks from COVID-19 and have produced antibodies. 

The plasma transfusion is a clinical trial to see whether anitbodies that their immune systems created would help those who are battling a more advanced stage of the coronavirus. The trial is the first of its kind in Louisiana and the third of its kind in the U.S.

“We will take their blood and run it through and siphon off the plasma, the plasma will have the antibodies and the antibodies will be administered to critically ill patients,” says LSUHS Chancellor Ghali.

MyArkLaMiss.com - Scientists at LSU Health Shreveport continue to have a significant impact on the fight against COVID-19 in Louisiana with their latest achievement being able to offer serology testing to support the Convalescent Plasma Therapy clinical trial and help identify ideal plasma donors.

Research from LSU Health Shreveport has shown that nitric oxide is a strong protector against tissue hypoxia, which occurs during severe Covid-1 infection”, said Dr. Chris Kevil, Vice Chancellor for Research at LSU Health Shreveport.

Keith Scott, MD, MSc, FCCM, Principal Investigator at LSU Health Shreveport for the nitric oxide clinical trial said, “We have tremendous confidence this therapy will alter the devastating effects of CoVID-19 but we must test it.”

The LSU Health Shreveport Department of Medicine has joined up with the Massachusetts General Hospital and the University of Alabama-Birmingham to enlist patients in a test study using inhaled nitric oxide to heal lungs damaged by COVID-19.

Research from LSU Health Shreveport has shown that nitric oxide is a strong protector against tissue hypoxia. “It’s just really a raging phenomenon that occurs in the lung and if we can just calm that down a little bit and allow the body’s natural systems to come in an heal it, that’s the real goal,” said Scott.

“What we’re so excited about is this, it’s FDA approved. Almost any hospital of any size already has a ventilator, already has the gas and if this is something that does work it could start being applied immediately,” said LSUHS Professor, Keith Scott, MD.

WBRZ News - “We know a lot of these things work, we just don’t know when they work the best. And that’s what we’re trying to figure out really right now is when, how much and where. And that’s the confusing part of this whole disease. It’s nothing like we’ve ever seen, nothing like medicine has ever seen,” Dr. Keith Scott said.

KTBS 3 - “What makes this so exciting is not only are we on the forefront, we are on the forefront of the forefront,” said Dr. Keith Scott, the principal investigator for the trial at LSU Health Shreveport. This is not the first time inhaled nitric oxide has been used to fight a coronavirus. It was used in 2004 during the SARS outbreak.

LSU Health Shreveport is now one of five sites in the world and the first in Louisiana involved in a clinical trial that assesses inhaled nitric oxide as a treatment for patients with mild to moderate cases of COVID-19.

318 Forum - Dr. John Vanchiere, professor of medicine and pediatrics, director of community testing and vaccinations and principal investigator for the Pfizer Vaccine Trial in north Louisiana at LSUHS, shares, "The CDC recommends that people ages 12 years and older receive one dose of the updated COVID-19 bivalent booster vaccine if it has been at least two months since their last vaccine dose."

Washington Examiner - The Biden administration's fall campaign to get people vaccinated with the omicron booster has been off to a slow start. Dr. John Vanchiere, director for community outreach for Center for Emerging Viral Threats at LSUHS, anticipates that more people will get the updated booster as it gets closer to Thanksgiving in preparation for traveling and visiting family.

NPR Red River Radio - Dr. Jeremy Kamil, LSUHS virologist, answers questions about the COVID-19 booster and when to get your flu shot.

Bossier Press-Tribune - The FDA-authorized bivalent COVID-19 vaccines, or updated boosters, are now available at LSUHS and include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19.

The LSU Health Shreveport COVID-19 Strike Teams reached a major milestone today having administered just over 100,000 VACCINATIONS. Over 175 individuals have been a part of the LSUHS vaccine teams comprised of physicians, nurses, nursing, medical and allied health students, and the Louisiana National Guard.

KTBS3 - Dr. John Vanchiere, the lead investigator in the Pfizer vaccine study at LSUHS said, “We expect that to take at least four to six weeks of time. And Pfizer and Moderna are both starting additional enrollment in the pediatric studies in that 5- to 11-year-old age range, so that they can get more data under the research protocol to submit to the FDA when it’s appropriate.”

KTBS3 - Dr. John Vanchiere, an infectious disease and pediatrics specialist and the lead investigator on the Pfizer vaccine study at LSU Health Shreveport, shares "Demonstrating effectiveness that is preventing hospitalization and death or severe disease is very challenging in the pediatric population, because kids don't get generally very sick."

StatNews - By cutting how much the virus replicates — both through preventing infections and by shortening the infections that do occur — vaccines limit the likelihood of additional, more dangerous variants. Says Jeremy Kamil, a virologist at LSUHS, “The virus has to replicate in order to mutate, but each virus doesn’t get many lottery tickets in a vaccinated person who’s infected.”

BBC - Dr, Jeremy Kamil, a virologist at LSUHS, says "I would be delighted that a vaccine company overcame the immense challenges to make it work. But it's imperative that the efficacy data be vetted independently."

KEEL - Dr. John Vanchiere, LSUHS Pediatric and Infectious Disease Specialist, explains, "Booster shots are recommended for individuals who are moderate to severe immune-compromised. It's the same vaccine, just like the second dose, you're going to get a third dose of the same thing."

Heavy.com -  Dr. Jeremy Kamil, Associate Professor of Microbiology and Immunology at LSUHS leads COVID-19 sequencing at the institution shared that he believes a doomsday variant is extremely unlikely and that people should be talking instead about the importance of getting vaccinated because variants can develop when large numbers of people do not.

Dr. John Vanchiere, Professor of Pediatrics and Infectious Disease at LSUHS served as was one of eight clinical leaders in Louisiana invited to participate in The Louisiana Community Engagement Alliance Against Covid-19 Disparities (LA-CEAL) Town Hall meeting which was designed to provided updated information on COVID-19.

New York Times - Facing deep mistrust stoked by rampant conspiracy theories, local health officials are fighting for influence when the only sure strategy for beating back the virus is getting more people vaccinated. “It’s a lot of small battles in different places,” Dr. John Vanchiere said, “and every battle is going to be different.”

Boston Globe - Dr. Jeremy Kamil, an associate professor of microbiology and immunology at LSUHS, oversees a team of scientists reading the genomes of positive virus samples each week. A run of samples this week found the number of cases involving the delta variant had exploded. Dr. John Vanchiere, a professor of infectious disease at LSUHS said a growing public awareness of local delta cases was one reason his team was now vaccinating twice as many people as a month ago — as many as 100 a day.

Boston 25 News - Dr. Jeremy Kamil, an associate professor of microbiology and immunology at LSU Health in Shreveport, Louisiana, calls the two-dose data very clear and very strong. “You can control your behavior and go back and get that second shot and do your part to protect our community and to protect our country from the pandemic having another big wave here."

BBC World - Even with 166 examples of Delta plus shared on GISAID, "we don't have much reason to believe this is any more dangerous than the original Delta," according to Dr Jeremy Kamil, a virologist at LSU Health Shreveport. "Delta plus might have a slight advantage at infecting and spreading between people previously infected earlier or who have weak or incomplete vaccine immunity."

NOLA.com - “This virus can get past the defenses that our bodies made against earlier pandemic viruses,” said Jeremy Kamil, a virologist who has been sequencing variants at LSU Health Shreveport. Being infected last summer will not necessarily protect someone from being infected by the delta variant.

KSLA 12 - Across Louisiana, more than 3 million doses of the vaccine have been placed in arms, while 1.4 million Louisianans are fully vaccinated — about 32% of the state. “The faster we can vaccinate ... the more difficult it is for these variants to emerge across the world, and we are seeing it,” LSUHS Dr. John Vanchiere said.

New York Times - The split is particularly stark in Britain, which is facing the spread of a new variant, while America has essentially lifted all rules for people who are vaccinated. “Globally, it’s a nightmare, because most of the world is still not vaccinated,” said Jeremy Kamil, a virologist at Louisiana State University Health Shreveport. “It raises the stakes.”

The74Million - “Until you get upwards of 80 percent of children vaccinated, you’re going to have a hard time going back to pre-pandemic practices without some risk of illness and death,” Jeremy Kamil, associate professor of microbiology and immunology at Louisiana State University Health Shreveport, told The 74.

KTBS - Dr. John Vanchiere, lead investigator on the Pfizer vaccine study at LSUHS said, “The vaccine is effective at several things. Number one, reducing people from getting sick from COVID and spreading it to other people. Big time important is that vaccination reduces hospitalization and death.”

CNN News 18 - India recorded on Monday 3,52,991 new Covid-19 cases and 2,812 deaths in the last 24 hours. The country saw 22.5 lakh new infections in the last one week, the highest ever the world has seen, pushing India’s health infrastructure to a brim.

“LSUHS is adjusting our strategy to accommodate more folks,” Dr. John Vanchiere said. “I would like to see longer lines and more people there getting vaccinated. And we have (the) capacity to vaccinate more than 2,000 or 2,500 people per day.”

NBC CT - LSU Health Shreveport Virologist Jeremy Kamil told NBC Connecticut Investigates that halting their spread will require other measures. Kamil was among a team of researchers that discovered seven new COVID-19 strains, known as "variants," aside from the variants first identified in the UK, South Africa, and Brazil. 

We are proud to announce that on February 24, 2021, 2:00 PM – 3:30 PM EST Dr. G.E. Ghali, Chancellor for LSU Health Shreveport has been invited to be part of a panel of four people on one of the Town Hall Sessions on the topic of Building Bridges between Public Health and Healthcare Systems to Ensure Equitable Vaccination.

Governor John Bel Edwards visited Louisiana’s first mass community vaccine clinic to see firsthand just how well the community effort involving LSU Health Shreveport faculty, students and staff, Region 7 Office of Public Health, Louisiana National Guard, BPCC nursing students, CHRISTUS Shreveport-Bossier Health System and Willis-Knighton Health System is working

Shreveport Times - Dr. John Vanchiere, professor and chief of pediatric infectious diseases at LSUHS, talked about the benefits of getting the vaccine and its safety. “We know that early on when people get infected with COVID-19, most people have no symptoms at all and that is one of the very critical features of this type of infection compared to influenza."

KTBS3 - While most Americans are still waiting to get the COVID-19 vaccine, some moms-to-be are worried about possible side effects to their unborn children.

KTBS 3 - “The quicker that people get vaccinated, the less chance of any virus being around and given the opportunity to mutate,” Dr. Ghali, LSU Health Shreveport Chancellor explained. “The longer a virus is around, the longer they're going to be able to mutate. It's a natural course in the development of the virus.”

This week LSU Health Shreveport took a historic step towards stopping the spread of the coronavirus. In addition to continuously testing for COVID-19, the Emerging Viral Threat Lab has now organized the distribution of the vaccine to individuals age 70 and up. On the first day of testing, over 1100 seniors were able to get the vaccine from the safety of their vehicles.

As it relates to COVID, each of us will make a choice about the vaccine. I choose to be vaccinated because I have seen the complications of COVID close up and have great faith in the scientific trials supporting this vaccine.

KSLA 12 - Dr. Robert Rhoads, professor and emeritus chairman of the Department of Biochemistry and Molecular Biology at LSU Health Shreveport, developed key components of the mRNA over years of work. The vaccine uses messenger RNA, or mRNA, which essentially provides instructions to the body on how to fight the novel coronavirus.

KSLA 12 - “It is gratifying to see LSU Health Shreveport’s contributions to the Pfizer-BioNTech vaccine through licensing of a LSUHS patent to BioNTech for mRNA-stabilizing cap analogs and in serving as the only north Louisiana vaccine trial site. Additionally our numerous COVID-19 clinical trials are providing access to novel therapies reflecting the benefit of having an academic medical center in our community,” shared Dr. G.E. Ghali, Chancellor of LSU Health Shreveport.

LSUHS is expanding enrollment in the Pfizer-sponsored COVID-19 vaccine study for the next two weeks to include individuals ages 16-18 and those older than 85 years of age.  Those interested in participating in this important vaccine trial should sign up as quickly as possible.  

KTBS 3 - LSU Health Shreveport announced this week that it is participating in the Pfizer COVID-19 vaccine study and is currently enrolling people to participate.

Louisiana Economic Development - LSU Health Shreveport scientists have discovered a promising new treatment for prostate cancer and developed a playbook detailing how to track viral variants in underserved areas.

Researchers from academic institutions in Louisiana, Mississippi and Georgia have partnered to publish a playbook detailing their model developed for establishing collaborative, community-centered infectious diseases surveillance programs committed to improving equity in genomic sequencing.

The Center for Emerging Viral Threats at LSUHS recently sequenced the first instances in Louisiana of the XBB.1.16 and XBB.1.9.1 variants. "Detecting these very recently emerging variants demonstrates the robustness of our efforts,” said Krista Queen, PhD, Director of Viral Genomics and Surveillance.

Dr. Krista Queen, Director of Viral and Genomic Surveillance for the CEVT, was invited to speak at the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) Network, organized by the World Health Organization.

The Louisiana Board of Regents has supported full five-year approval for the Louisiana Addiction Research Center (LARC) and Center for Emerging Viral Threats (CEVT), with the CEVT continuing to be a designated Center of Research Excellence. The Board of Regents approval follows unanimous approval of both centers by the LSU Board of Supervisors earlier this year. Both centers were previously granted provisional approval and applied for full center approval earlier this year.

The Center of Excellence for Emerging Viral Threats’ (CEVT) Viral Genomics and Surveillance Lab has surpassed uploading its’ 15,000^th sequence to GISAID (Global Initiative on Sharing Influenza Data). The LSU Health Shreveport CEVT team has worked tirelessly since early in the COVID-19 pandemic to sequence and track variants of SAR-CoV-2, the virus that causes the COVID-19 disease.

Popular Science - The BA.5 wave may not overwhelm hospitals to the degree seen last winter, although emergency rooms and ICUs are already stretched thin. “But there’s definitely going to be an increase to some degree,” says Dr. Jeremy Kamil, a virologist who has led sequencing at LSUHS.

Louisiana Senator Bill Cassidy was instrumental in the receipt of this funding for LSUHS, which will enhance the impact of the Center for Emerging Viral Threats (CEVT) as it is able to expand significantly in the new Center for Medical Education building. Additional medical education and research opportunities will yield enhanced economic impact to the region and the state.

NPR Red River Radio - Health Matters: Andrew Yurochko, PhD and Krista Queen, PhD talk about COVID Sequencing – why it matters and how LSU Health Shreveport is contributing to this international conversation. 

41NBC - Mercer University School of Medicine, in partnership with the Department of Biomedical Sciences and LSU Health Shreveport, was recently awarded a $25,000 grant from the Rockefeller Foundation. The money will help to guide Covid-19 research about possible variants of the virus.

KTBS3 - The LSUHS COVID-19 Strike team and Emerging Viral Threats lab hit a record high with over 14,000 COVID-19 tests conducted last week. This is quite a feat, considering many areas across the country have had to scale back testing to symptomatic people only because staff members and labs were overrun.

KSLA12 - Sequencing is a multi-step process that includes using robotic technology to help make the process faster, more efficient and to reduce human error. "While this new variant has more mutations than others, her team is much more equipped this time around," says Dr. Krista Queen, Director of Viral Genomics and Surveillance for LSUHS.

Shreveport Times - Research Notebook: Since the earliest days of the COVID-19 pandemic scientists around the world have been working together on critical genomic sequencing efforts to better understand how the SARS-CoV-2 virus spreads and evolves and help guide and evaluate public health response. 

Bloomberg - While the U.S. is sequencing a much higher percentage of Covid samples than earlier, the bigger issue may be that not enough virus testing is done in the first place, said Jeremy Kamil, a virologist at Louisiana State University Health Shreveport.

Read the Full Article in PDF

A new variant of COVID-19 has been identified in Louisiana by scientists at the LSU Health Shreveport Emerging Viral Threats Center. LSUHS announced this month that the B.1.630 variant had been sequenced and reported by the center, though health officials believe this variant's predominance is very low and much less transmissable than the deadly delta variant.

The EVT Viral Genomics and Sequencing Lab at LSU Health Shreveport is first in the state to sequence and report that a new variant of SARS-CoV-2, the virus that causes COVID-19, has been detected in Louisiana. The new variant, B.1.630, was sequenced last week from two samples collected in Baton Rouge.

LSU Health Shreveport has been on the front line fighting the COVID-19 pandemic since the beginning. The establishment of the Emerging Viral Threats lab in March of 2020 led to mass testing and vaccination sites, clinical trials in patient treatment options and viral sequencing that discovered 7 COVID-19. variants.

Louisiana Radio Network - The objective of the grant is to strengthen global capabilities to detect and respond to pandemic threats in the future. Director for Emerging Viral Threats at LSUHS Dr. Andrew Yurochko said the award is indicative of LSU Health Shreveport’s strides in detecting variants and assisting with vaccine rollout.

Red River Radio - Work by Drs. Jeremy Kamil and Rona Scott along with COBRE principal investigators Drs. Andrew Yurochko and Chris Kevil has produced and shared 2,839 full coverage SARS-CoV-2 genomes, which amounts to over 60% of the SARSCoV-2 genome surveillance from Louisiana, and 1.2 % of the total US data submitted to GISAID which is the Global Initiative on Sharing All Influenza Data.

The Rockefeller Foundation - LSU Health Shreveport (LSUHS) is receiving funding ($340,000) from the Rockefeller Foundation. This follows the announcement yesterday of LSUHS being awarded $730,000 to further its work in genomic sequencing of COVID-19 through a NIH supplemental grant.  LSUHS joins Harvard and the Broad Institute at MIT among others in the US Regional Accelerators for Genomic Surveillance.

KTBS-3 - The Center of Excellence for Emerging Viral Threats at LSU Health Shreveport plays a big role in COVID-19 testing and community vaccinations. But another important role it plays involves the identification of COVID-19 mutations and the variants they cause.

Fortune.com - Even the type of sequencing done in the U.S. has been lacking, some experts say, with much of the effort focused on finding cases of the U.K. variant, rather than casting a wider net for any variant, including ones not previously identified, said Jeremy Kamil, a virologist at Louisiana State University Health Shreveport.

Bloomberg.com - Even the type of sequencing done in the U.S. has been lacking, some experts say, with much of the effort focused on finding cases of the U.K. variant, rather than casting a wider net for any variant, including ones not previously identified, said Jeremy Kamil, a virologist at LSU Health Shreveport. “It’s the Wild West,” he said. “Every state, city, county is doing its own thing. It’s a bunch of random cats and no one is trying to herd them.”

Shreveport Times - LSU Health Shreveport's Dr. Jeremy Kamil talks about the importance of genome sequencing during COVID-19.

KSLA 12- “If the EVT Lab had not existed, quite frankly, I think we’d be in a much darker place here in the northern part of the state,” said Dr. Chris Kevil, vice chancellor of research and one of the leading minds behind creation of the lab. “The EVT Lab has been fundamental in our ability to monitor COVID infections in patients out in this community."

MSN.com - The Emerging Viral Threat (EVT) Lab at LSU Health Shreveport has now sequenced a total 651 Louisiana SARS-CoV-2 virus genomes making it the largest contributor to date of genetic data on SARS-CoV-2 in the state. 

The Emerging Viral Threat (EVT) Lab at LSU Health Shreveport has now sequenced a total 651 Louisiana SARS-CoV-2 virus genomes making them the largest contributor to date of genetic data on SARS-CoV-2 in the state. SARS-CoV-2, which is short for ‘Severe Acute Respiratory Syndrome Coronavirus-2,’ is the virus that causes COVID-19, and viral genome sequencing is contributing to a worldwide effort to fight the ongoing pandemic.

KTBS 3 - Andrew Yurochko, Professor of Microbiology and Immunology at LSUHS, shares, “When you think about total tests, 0.1% of the total tests of the entire country are done right here in Northwest Louisiana, where we’ve focused on our own citizens, not just in Shreveport or Caddo Parish, but in all of Region 7 which is Northwest Louisiana.”

The Emerging Viral Threat Lab at LSU Health Shreveport has processed over 110,000 COVID-19 test samples from multiple public health regions of the state and created over 170,000 test kits which were distributed throughout the state during its first six months of operation.

The Daily Beast - "Louisiana is getting pummeled by the virus. But without a comprehensive early testing program in Shreveport, it would have been worse still."

Shreveport Times - From the formulation of an emerging viral threat lab to community testing, LSU Health Shreveport has actively fought COVID-19. Dr. Chris Kevil talks about testing, clinical trials and prevention.

Rick Rowe, KTBS-3 News, talks to EVT Lab scientists and researchers at LSUHS about the work they are doing that is saving lives.

Nextstrain reports new sequences from Belgium (19), Italy (12), Uganda (20) and the USA (95). The 95 new Louisiana sequences, provided by the LSUHS EVT Lab are shown together with older samples from Louisiana.

“Our unique team of women made the vision for the EVT Lab a reality. They are the true beating heart of the lab,” said Andrew Yurochko, PhD “Without them, there is no way this would be possible. As a group, they have worked the longest and hardest hours. They are really the superheroes.”

The Lions Club District 8L received a grant from the Lions Club International Foundation that has resulted in a donation to the Emerging Viral Threat (EVT) Lab at LSU Health Shreveport.

LSU Health Shreveport is now one of five sites in the world and the first in Louisiana involved in a clinical trial that assesses inhaled nitric oxide as a treatment for patients with mild to moderate cases of COVID-19.

WBRZ News - “We know a lot of these things work, we just don’t know when they work the best. And that’s what we’re trying to figure out really right now is when, how much and where. And that’s the confusing part of this whole disease. It’s nothing like we’ve ever seen, nothing like medicine has ever seen,” Dr. Keith Scott said.

As part of a national cooperative with the University of South Florida (USF) Health, Northwell Health, New York’s largest healthcare provider, and Formlabs, LSU Health Shreveport has obtained the printing files for a patented swab design, becoming the first in Louisiana to produce these patented 3D-printed swabs.

LSU Health Shreveport is bringing testing online that will allow them to check a person’s blood for antibodies that may indicate they are immune to coronavirus.

MyArkLaMiss.com - Scientists at LSU Health Shreveport continue to have a significant impact on the fight against COVID-19 in Louisiana with their latest achievement being able to offer serology testing to support the Convalescent Plasma Therapy clinical trial and help identify ideal plasma donors.

Phase two in the fight against COVID-19 is ramping up. The fight began with testing, now it's the race to find a treatment and eventually a vaccine. Convalescent plasma is so far showing great promise.

To begin opening the state back up, Edwards has said officials need far more diagnostic tests, along with serological tests that could tell whether people have immunity to the virus. 

"In general, you have to be symptomatic so the van can go an test them. The test itself is a very short test. I mean, it doesn't take long to do a nose swab. So, you can do an area in a couple of hours," Arnold said. 

Commissioner Jackson said, “This is particularly for individuals who are medically underserved or have access barriers. We want to go off data with the Health Unit to see where there is significant community spread and be aggressive with testing.”

Dr. Martin Sapp, Chair of Microbiology at LSUHS, shares how the EVT Lab will help with current and future viral threats.

The Shreveport Times reached out to Professor Andrew Yurochko, Carroll Feist endowed chair of viral oncology and department vice-chair of microbiology and immunology, LSUHS, with the Emerging Viral Threat lab which began processing COVID-19 samples last Wednesday.

Dr. Kevil, in reference to the EVT lab says, "We're ramping up to get to get from about 1,000 to a peak of 2,000 tests a day. Right now we're in the process of working out...a system (between) the clinical laboratory, the hospital and the community so that we can provide the turnaround time of the test of 48 hours, working to get it down to 24 hours."

Chancellor Ghali explains the medical school's growing role in the COVID 19 fight. "We already have a robust and incredibly well known virology department," he says, adding that their experience in SARS virus research laid the groundwork for this challenge. "What (our) lab allows us to do is test up to about 2,000 samples a day." Ghali says these samples are coming to LSUHS from all over the country.

As the coronavirus spreads, researchers at academic medical institutions have jumped into the containment battle by developing and deploying tests to detect the virus. They hope to help fill a nationwide shortage of such tests. (AAMC.org)

Forbes.com - Biomedical researchers at Louisiana State University Health Shreveport set up an Emerging Viral threat Lab to process COVID-19 tests with a short turnaround time.

On Wednesday morning, LSU Health Shreveport held a virtual press conference to announce that it has established a COVID-19 testing lab. Officially, the testing lab facility will be known as the Emerging Viral Threat Lab (EVT). 

LSU Health Shreveport has established the Emerging Viral Threat (EVT) Laboratory to address the need for faster detection and processing of COVID-19 tests.

Dr. G. E. Ghali, chancellor of LSUHS, said during a Wednesday press conference that, “Around the 17 of March, I approached the governor and said we have a few road blocks to this and we need your help. Without any questions he jumped right in and created an executive order and by March 25, today, the lab is up and running.”

The EVT Lab is the first in north Louisiana approved by CMS to conduct and analyze tests to determine if an individual has COVID-19.

During a virtual press conference Wednesday morning, Chancellor G. E. Ghali said the facts around Louisiana’s confirmed cases are “really scary” because studies show the state has the fastest growth rate of confirmed cases in the entire world, third in per capita, and the steepness parallels that of Italy and Spain.

Top scientists at LSUHS have created the Emerging Viral Threat Lab in a remarkable amount of time to take on the global pandemic. The (EVT) Lab can initially test 50 samples per day and expects to tests in the hundreds by end of the week and into next week. The test results are determined with 24 to 48 hours. 

Having an academic medical center is a “gem” touted frequently throughout north Louisiana and beyond. While many in the nation are fearful of having appropriate access to testing and quality care during the Covid-19 pandemic, thanks to LSU Health Shreveport, north Louisiana is infinitely better positioned than most communities to face Covid-19.

Red River Radio - Dr. John Vanchiere, LSUHS Professor of Pediatrics and Senior Associate Dean for Clinical Research, participated in a discussion about the rise in strep infections and dengue fever, the latest COVID variants, bird flu and more.

KSLA12 - With the CDC reporting a rise in COVID cases, Dr. Alexandre Malek, LSUHS Director of Infectious Disease Research, talks about the newly approved FDA updated COVID vaccines.

KSLA12 - Doctors say they are seeing the usual summer surge in COVID-19 cases.“This is the COVID normal that we’ve seen the past four years,” said Dr. John Vanchiere, LSUHS pediatric infectious disease specialist.

The Mercury News - “Through multiple immunizations, your repertoire of immune cells expands,” said Jeremy Kamil, a virologist at LSUHS, who studies variant mutations. “Your body learns to make these very potent antibodies that are active against multiple strains of the virus."

Shreveport Times - Dr. Krista Queen, Director of the Viral Genomics and Surveillance Center for Emerging Viral Threats at LSUHS, said, "FLiRT is an interesting name for this new variant and it's referring to a couple of different mutations that are present and actually it's not just one variant, it's a group of variants."

NPR Red River Radio -  Jeremy Kamil, a virologist at LSUHS, says that if you get a mild infection, "your body's not going to respond with its most heavy armaments as it would when you get a [more severe] infection." That latter bodily response is what triggers longer lasting immunity. 

CNN - According to new documents shared with U.S. lawmakers this week, the genetic sequence of the coronavirus was submitted to an NIH database two weeks before the Chinese government disclosed its findings.

Science - Lawmakers say delay in making the sequence public held up vaccine work. The never-completed GenBank submission was “a huge missed opportunity” to start to develop drugs, diagnostics, and vaccines earlier, agrees virologist Jeremy Kamil of LSUHS.

New York Times - Newly released documents indicate that a U.S. genetic database had received the sequence of the coronavirus two weeks before it was made public by others.

NPR Red River Radio - "The most reliable data shows that a surge is happening," says Jeremy Kamil, a virologist at LSUHS. If your whole family gets COVID, isolating will only "cause you inconvenience and additional misery on top of feeling tired and ill."

KSLA12 - Dr. Evelyn Pryor, LSUHS Division Chief of General Medicine, said, relatively speaking, COVID is fairly controlled but this is the worst flu season they’ve seen since 2019 and these illnesses tend to peak in January.

The Wall Street Journal - Jeremy Kamil, a virologist at LSUHS, says Covid-19 is constantly evolving and finding ways to evade our immune system. The antibodies produced in response to an earlier infection or vaccination might not be as effective at staving off a new variant.

Wall Street Journal - Do Covid-19 vaccines work against JN.1? “Data shows that all of the antibodies are a really good fit, luckily, for JN.1,” said Jeremy Kamil, a virologist at LSUHS. “That’s really good news.”

KTBS3 - "The best data that I’ve seen is that around four to five percent of people will experience symptoms even after four months," said Dr. John Vanchiere, LSUHS Associate Professor of Medicine, Pediatrics and Infectious Diseases.

KTBS3 - Dr. John Vanchiere, LSUHS associate professor of Pediatrics, emphasizes the prudence of mask-wearing, especially within the confines of airports and aircraf, advocating for the use of a simple surgical mask, highlighting its effectiveness in reducing the risk of viral transmission. 

Louisiana Economic Development - LSU Health Shreveport scientists have discovered a promising new treatment for prostate cancer and developed a playbook detailing how to track viral variants in underserved areas.

SBC Advocate - "The winter surge tends to be more intense with higher case counts and a shorter duration of time," shared Dr. John Vanchiere, assistant vice chancellor for clinical research at LSUHS.

KTBS 3 -  Dr. John Vanchiere, LSUHS Associate Professor, shares, "A couple of weeks between vaccines is plenty enough time, but it's okay to go ahead and get all three at once. Your immune system can definitely handle it."

KTAL6 - The medical community advises high-risk people to continue to use precautions such as wearing a mask, keeping their distance, and washing their hands.  Most people who become infected will have a mild case.

KSLA12 - ”There has been an increase in COVID related hospitalizations again. Not nearly as many as in prior surges but definitely an increase, and that’s seen locally and nationwide,” Dr. John Vanchiere, Associate Vice Chancellor for Clinical Research at LSUHS  said.

Shreveport Times - "Knowledge is power," said Dr. Krista Queen. "If you get tested and you're positive, you can implement some changes to make sure you reduce the risk to those around you."

Webtimes.UK - Dr. Jeremy Kamil, Associate Professor of Microbiology and Immunology at LSUHS shares, "I’d rather have people complaining that we’re not naming enough than that we’re naming too many. It’s like if you sound a fire alarm all the time, people will stop evacuating the building quickly.”

KTAL 6 - Dr. Krista Queen, Director of Viral Genomics and Surveillance for the Center for Emerging Threats at LSUHS, shares there’s increased transmissibility of the new variant, ... but we’re not seeing increased disease severity.

Researchers from academic institutions in Louisiana, Mississippi and Georgia have partnered to publish a playbook detailing their model developed for establishing collaborative, community-centered infectious diseases surveillance programs committed to improving equity in genomic sequencing.

SB Advocate - LSUHS Associate Director for Clinical Outreach, Dr. John Vanchiere said, "Based on the pattern of COVID activity over the past three years, we do expect to see a winter-time spike in COVID cases, probably beginning in December and peaking in February..."

The Center for Emerging Viral Threats at LSUHS recently sequenced the first instances in Louisiana of the XBB.1.16 and XBB.1.9.1 variants. "Detecting these very recently emerging variants demonstrates the robustness of our efforts,” said Krista Queen, PhD, Director of Viral Genomics and Surveillance.

Dr. Krista Queen, Director of Viral and Genomic Surveillance for the CEVT, was invited to speak at the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) Network, organized by the World Health Organization.

Vax Matters - Dr. Jeremy Kamil, Associate Professor of Microbiology and Immunology at LSUHS, shares answers to why viruses change, bringing his wealth of knowledge in virus and disease spread.

KNX News - A discussion with LSUHS virologist Jeremy Kamil who reviewed the study on the new research into origins of COVID-19 that connect raccoon dogs to the virus.

NY Times - Genetic samples from the market were recently uploaded to an international database and then removed after scientists asked China about them. LSUHS virologist, Dr. Jeremy Kamil said that fell short of conclusive evidence that an infected animal had set off the pandemic.

ABC News - Researchers analyzed genetic data from samples taken at the Wuhan market. "In samples with a hot amount of virus, there was not a trivial amount of DNA and RNA of raccoon dogs," Dr. Jeremy Kamil, associate professor of microbiology and immunology at LSUHS, told ABC News.

FORTUNE - "The studies don't exclude other hypotheses entirely. But they absolutely are pushing it toward an animal origin,” virologist Jeremy Kamil, at LSU Health Shreveport, told NPR at the time.

KTBS3 - “It’s important not to trivialize this virus. We’re all back to living as we did before, and I think the best tool we have in our arsenal is to stay current on the vaccine doses,” said Dr. Jeremy Kamil, virologist at LSUHS.

NOLA.com - Jeremy Kamil, LSUHS virologist, said, "It's a little bit uncertain how serious of a contender this virus is outside of New York, where XBB.1.5 was first discovered.

Shreveport Times - The Center of Excellence for Emerging Viral Threats (CEEVT) and its wastewater monitoring laboratory at LSU Health Shreveport have been testing wastewater samples to monitor the spread of COVID-19 in local communities.

KTAL6 - Dr. Krista Queen with LSUHS says the COVID positivity rate in our area population is six percent. About two months ago, it was just below five percent. She says this is due to social dynamics returning to pre-pandemic norms and people not taking the same precautions.

KTBS3 - A medical triple threat—COVID-19, Influenza, and Respiratory syncytial virus, or RVS, has been ravaging U.S. health systems competing for attention.

NPR Red River Radio - "This virus is getting a lot of lottery tickets if you will. And it looks like, with these new variants, these new mutations are like the jackpot," says Jeremy Kamil, an immunologist at LSUHS. 

Mercury News - The (new) variants look a lot like the virus that was the template of our new bivalent booster, so vaccination still works. “It’s not a perfect match … but it’s close,” said Jeremy Kamil, a virologist at LSUHS, who studies variant mutations. “In most cases, that’s going to keep the infection in check.”

318 Forum - Dr. John Vanchiere, professor of medicine and pediatrics, director of community testing and vaccinations and principal investigator for the Pfizer Vaccine Trial in north Louisiana at LSUHS, shares, "The CDC recommends that people ages 12 years and older receive one dose of the updated COVID-19 bivalent booster vaccine if it has been at least two months since their last vaccine dose."

Washington Examiner - The Biden administration's fall campaign to get people vaccinated with the omicron booster has been off to a slow start. Dr. John Vanchiere, director for community outreach for Center for Emerging Viral Threats at LSUHS, anticipates that more people will get the updated booster as it gets closer to Thanksgiving in preparation for traveling and visiting family.

Bloomberg - Jeremy Kamil, virologist and professor of microbiology and immunology at LSUHS, shares, "Vaccinated and previously infected people have robust and still-intact lines of defense, such as memory T-cells and B-cells. People previously infected also have additional immune cells that reside in the respiratory tract."

KSLA12 - Health officials expect a rise in the number of COVID-19 cases as the colder months set in. That’s due, in part, to the fact that people will be in more confined spaces.But Dr. John Vanchiere, infectious disease specialist at LSUHS, noted also that vaccination rates are lower.

Nature.com - Jeremy Kamil, a virologist at Louisiana State University Health Shreveport shared, “The world needs to see more collaborations like this. Speed is crucial when it comes to fighting the virus.”

318 Forum - The 155,000-square-foot Center for Medical Education will be home to large classroom spaces, clinical skills labs and simulation suites – each designed to encourage collaboration, active engagement and innovative thinking. 

NPR Red River Radio - Dr. Jeremy Kamil, LSUHS virologist, answers questions about the COVID-19 booster and when to get your flu shot.

CBC News - A recent spike in cases and hospitalizations in the U.K. have scientists bracing for potential winter waves. Dr. Jeremy Kamil, a virologist at LSUHS shares, "But the possibility that they're going to cause hospitals to be overwhelmed is what I want to dial people back on because we're not seeing any signs of that."

Bossier Press-Tribune - The FDA-authorized bivalent COVID-19 vaccines, or updated boosters, are now available at LSUHS and include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19.

Medscape - Dr. Jeremy Kamil, Associate Professor of Microbiology and Immunology at LSUHS talks with Medscape about the importance of virology in addressing concerns over hot topic viruses.

Washington Examiner - Jeremy Kamil, a virologist at LSUHS, said the months it will have taken to get an updated booster since identifying the omicron variant last November is "unacceptable," resulting in many people getting infected with omicron and needlessly getting sick as previous vaccines proved less effective against the variant.

KTBS3 - While less common than with adults, 5 to 10% of kids have residual symptoms as late as 12 weeks later. And some problems can be very serious, said Dr. John Vanchiere, LSU Health Shreveport pediatrics professor said.

The Louisiana Board of Regents has supported full five-year approval for the Louisiana Addiction Research Center (LARC) and Center for Emerging Viral Threats (CEVT), with the CEVT continuing to be a designated Center of Research Excellence. The Board of Regents approval follows unanimous approval of both centers by the LSU Board of Supervisors earlier this year. Both centers were previously granted provisional approval and applied for full center approval earlier this year.

318 Forum Magazine - At this time, mask-wearing, hand washing and being “up to date” on your vaccine are the optimal prevention tools for contracting COVID and preventing severe illness. Dr. Andrew Yurochko and Dr. John Vanchiere of LSUHS share the latest on COVID-19.

KSLA 12 - Research experts and medical professionals from LSU Health Shreveport were joined by community leaders to provide an update on the COVID-19 pandemic. Speakers informed the community about the latest case numbers and efforts to increase vaccination rates.

The Center of Excellence for Emerging Viral Threats’ (CEVT) Viral Genomics and Surveillance Lab has surpassed uploading its’ 15,000^th sequence to GISAID (Global Initiative on Sharing Influenza Data). The LSU Health Shreveport CEVT team has worked tirelessly since early in the COVID-19 pandemic to sequence and track variants of SAR-CoV-2, the virus that causes the COVID-19 disease.

Red River Radio - Health Matters: Dr. John Vanchiere, Professor and Chief, Section of Pediatric Infectious Diseases and Krista Queen, PhD, Director of Viral Genomic and Surveillance at LSUHS talk about conronavirus variants.

KSLA 12 - Dr. John Vanchiere, professor of pediatrics at LSU Health Shreveport said Louisiana ranks 45th and 46th in vaccination for COVID among those ages five to 11 and 11 to 15, respectively. He said he expects the number of cases to grow when students go back to school.

NY Times - Opinion - Dr. Jeremy Kamil, ... , shares "As a virologist, it’s important to me that people understand Covid-19 remains a great concern. But this does not excuse or license a misdiagnosis of the current situation."

Popular Science - The BA.5 wave may not overwhelm hospitals to the degree seen last winter, although emergency rooms and ICUs are already stretched thin. “But there’s definitely going to be an increase to some degree,” says Dr. Jeremy Kamil, a virologist who has led sequencing at LSUHS.

KTBS3 - Dr. John Vanchiere, the director of clinical research and the COVID-19 Strike Team director for LSU Health Shreveport, says people start feeling better within a day or two after their first dose of Paxolovid, however there can be side effects.  

KTAL6 -  Local health experts say the BA.2 omicron variant of the coronavirus has been on the rise across the country and is now the dominant strain in NW Louisiana. “As mysteriously as the virus came on, it’s kind of evolved and become a little less problematic when people get it,” said Dr. Michael Sewell, Section Chief for Division of Internal Medicine / Hospitalist Program.

KSLA12 - Beginning Tuesday, April 19, the Center for Emerging Viral Threats (CEVT) at LSUHS will no longer offer COVID-19 testing at its North Campus site. This change is due to the low number of COVID-19 cases reported in recent weeks. A look at the Louisiana Department of Health’s COVID case map shows the cases are low across the state.

Boston25 - “We are seeing the prevalence of BA.2 increasing as the overall Omicron wave has crashed,” said Jeremy Kamil, PhD, associate professor of Microbiology and Immunology at Louisiana State University in Shreveport. “It is spreading. It can infect people who were previously vaccinated, particularly if they didn’t have a case of BA1.”

KTBS3 - Shelly Raley, the Program Coordinator for the LSUHS COVID Strike Team, says that circumstances make this current slowdown more calming than previous ones. "Currently there is no big delta or omicron that we see headed our way in the immediate future."

Louisiana Senator Bill Cassidy was instrumental in the receipt of this funding for LSUHS, which will enhance the impact of the Center for Emerging Viral Threats (CEVT) as it is able to expand significantly in the new Center for Medical Education building. Additional medical education and research opportunities will yield enhanced economic impact to the region and the state.

NBC News - Scientists have detected a handful of cases of the delta-omicron hybrid but say it's unlikely to cause a new surge. Dr. Jeremy Kamil, an associate professor of microbiology and immunology at LSUHS says, "Delta basically grabbed omicron's spike protein. This is essentially delta trying to hang on by plagiarizing from omicron."

Bloomberg - “I’m convinced that home testing is artificially lowering rates … and by a  lot,” says Jeremy Kamil, a virologist at LSUHS. “Especially when you factor in the additional impact of mild cases and pandemic fatigue.”

NPR - Dr. Jeremy Kamil, LSUHS Virologist, says these studies, along with several others published recently, are really tipping the scales toward an animal origin.

NPR Red River Radio - Health Matters: Andrew Yurochko, PhD and Krista Queen, PhD talk about COVID Sequencing – why it matters and how LSU Health Shreveport is contributing to this international conversation. 

Bloomberg - “No tests can tell you for sure what variant you have without full viral genome sequencing,” says Jeremy Kamil, a microbiologist and immunologist at LSU Health Shreveport. In the U.S., current federal guidance prevents labs from informing patients or their physicians about the specific genome-sequencing results.

The Philadelphia Inquirer - In addition to becoming more abundant with each exposure, the antibody response becomes more “mature,” saidDr. Jeremy Kamil, associate professor at LSUHS.

New York Times - “Expect the next variant to come out of left field,” said Jeremy Kamil, a virologist at LSU Health Shreveport. He added, “It’d be a hugely foolish thing for anyone to speak with excessive certainty about what’s coming in the next two years.”

NPR/Red River Radio - Health Matters: As the Omicron variant is surging in our region and across the country, Dr. Sanford Katz hosts this episode of Health Matters with guests Dr. John Vanchiere, Director of LSU Health Shreveport COVID-19 Community Testing and Vaccinations.

41NBC - Mercer University School of Medicine, in partnership with the Department of Biomedical Sciences and LSU Health Shreveport, was recently awarded a $25,000 grant from the Rockefeller Foundation. The money will help to guide Covid-19 research about possible variants of the virus.

Tittle Press - “It’s mostly that runny nose, sore throat, and nasal congestion,” said John Vanchiere, MD, PhD, associate director of the Center for Emerging Viral Threats at Ochsner LSU Health Shreveport (La.). NPR.

“These gifts will provide fundamental support for the CEVT for years to come as we continue to address the public health needs of the North Louisiana region and beyond,” said LSU Health Shreveport Vice Chancellor for Research, Chris Kevil, PhD

iNews.co.uk - Jeremy Kamil, virologist and associate professor at Louisiana State University Health Shreveport, told i: “SARS-Cov-2 is not going to become a ‘common cold’ / ordinary ‘seasonal’ coronavirus within the span of the next few months or even years.”

Today UK News - Jeremy Kamil, a virologist at LSUHS, agreed the world is now “well equipped” for the fight but viruses are always coming up with “countermeasures”. He suggests Covid could become more stealthy, like tuberculosis or HIV, with a longer “silent” phase of infection. (image: WHO)

NPR / Red River Radio - As the Omicron variant is surging in our region and across the country, Dr. John Vanchiere, Director of LSUHS COVID-19 Community Testing and Vaccinations, talks about how people are faring with this variant, testing and treatments, new isolation recommendations, and more.

KTBS3 - The LSUHS COVID-19 Strike team and Emerging Viral Threats lab hit a record high with over 14,000 COVID-19 tests conducted last week. This is quite a feat, considering many areas across the country have had to scale back testing to symptomatic people only because staff members and labs were overrun.

Eat This, Not That! - For many people, respiratory symptoms are the first sign of Omicron. "It's mostly that runny nose, sore throat and nasal congestion," Dr. John Vanchiere, the associate director of the Center for Emerging Viral Threats at LSU Health Shreveport, told NPR.

KSLA12 - Dr. Wanda Thomas, Associate Professor of Pediatrics at LSU Health Shreveport, explained the connection between COVID-19 and diabetes in children. 

KSLA12 - Dr. Suzanne Tinsley, Associate Professor of Physical Therapy at LSUHS, shares insights on study findings related to the impact COVID-19 can have on mobility.

NPR - "It's mostly that runny nose, sore throat and nasal congestion," says Dr. John Vanchiere, the associate director of the Center for Emerging Viral Threats at LSU Health Shreveport. "The cough is milder [than previous variants], if there's any cough at all, and fever seems to be a little less common."

Effective Wednesday, January 5, LSUHS will move its community COVID-19 testing and vaccination efforts back to the Louisiana State Fairgrounds located at 3701 Hudson Ave. to reduce wait times and accommodate more individuals each day. 

Dr. John Vanchiere, an infectious disease specialist at LSU Health Shreveport, agrees. “We are seeing significant increases in our positivity rates in our community testing and, unfortunately, also in our nursing home testing.

Shreveport Times - Despite the increased attention of omicron, delta continues to be the main variant in Louisiana, however, Dr. John Vanchiere, an infectious disease expert and Associate Director of the Center for Emerging Viral Threats at LSUHS, believes that could change much faster than some might think.

TheBulletin.org - Associate professor of microbiology and immunology at LSUHS Jeremy Kamil said he is “not at all convinced” that the current vaccines will continue to be protective “indefinitely.” "We just need to update our shot to show our body a repertoire that encompasses the variability at the key sites for neutralization"

KSLA12 - Sequencing is a multi-step process that includes using robotic technology to help make the process faster, more efficient and to reduce human error. "While this new variant has more mutations than others, her team is much more equipped this time around," says Dr. Krista Queen, Director of Viral Genomics and Surveillance for LSUHS.

Shreveport Times - "The definitive 'are we protected' is not known yet, and won't be for a couple of weeks. Based on the sequencing and what we know about the protection of the vaccine, we expect there will be some protection," shared Dr. John Vanchiere, Infectious Disease Specialist at LSUHS. CDC updates on Omicron Variant

Shreveport Times - Research Notebook: Since the earliest days of the COVID-19 pandemic scientists around the world have been working together on critical genomic sequencing efforts to better understand how the SARS-CoV-2 virus spreads and evolves and help guide and evaluate public health response. 

Roy O. Martin III and Kathy Martin have donated $500,000 to the Center for Medical Education as part of a larger LSU system-wide gift supporting top capital priorities for the Fierce for the Future Campaign. The Martin’s gift will be directed to the Center of Excellence for Emerging Viral Threats (CEVT) to be housed on the top floor of the Center for Medical Education.

KTAL/KMSS - Local infectious disease expert and LSU Health Shreveport Director of Testing and Vaccines says the findings of a small study showing Pfizer’s booster offers strong protection against the fast-spreading omicron variant are promising, but it will be a few more weeks before we know just how effective it is.

“It is very important for folks to get vaccinated against flu and COVID so that we can, prevent illness and death in the community and keep folks out of the hospital. And reduce the transmission of these to other people who may not be able to be vaccinated,” said Dr. John Vanchiere, infectious disease specialist at LSUHS.

Financial Times - Labs are scrambling to answer 3 fundamental questions: is it more transmissible, can it evade the vaccination, and does it cause more severe disease? Jeremy Kamil, a virologist studying Sars-Cov-2 evolution at LSUHS, describes his shock when this genome was released. “It was like coming home from vacation and seeing that someone hasn’t just planted a few flowers in your garden. They’ve remodeled the whole landscape.”

KSLA12 - Dr. John Vanchiere shares "We've seen the variants over the past two years emerge and each was more transmissible than the prior one. The early data appears that this omicron variant may even be more transmissible than delta." 

KTBS3 - Jeremy Kamil, PhD., a virologist at LSU Health Shreveport, says the Omicron variant was first found on Nov. 11. What the South African scientists discovered was that this new variant is a lot different than the ones that have been seen so far. "This one is very extensively mutated.”

Bloomberg - While the U.S. is sequencing a much higher percentage of Covid samples than earlier, the bigger issue may be that not enough virus testing is done in the first place, said Jeremy Kamil, a virologist at Louisiana State University Health Shreveport.

Read the Full Article in PDF

News Star - Louisiana Tech University, Grambling State University, LSU Health Shreveport and several health clinics across the region are working together to sequence the COVID-19 virus to learn how it's spreading and if any new variants arise. Research from the three universities is made available for the public online at nla-health.com.

An official release of five PSAs created by five student filmmakers from the Northwest Louisiana area was held on November 22nd at LSUHS as part of a collaboration between the Film Prize Junior program and LSUHS, followed by Q&A sessions about this project.

Louisiana Radio Network - LSU-Health Shreveport is helping parents by making it as convenient as possible to have children ages five to eleven get vaccinated at schools in north Louisiana. 

KTBS3 - “It's not an emergency, it's not a ‘got to do this before the winter’ kind of thing,” said Dr. John Vanchiere, director of COVID-19 community testing and vaccinations at LSUHS. “We’d rather have more young adults get vaccinated, than use boosters in that age group at this point. That would be much more effective."

The LSU Health Shreveport COVID-19 Strike Teams reached a major milestone today having administered just over 100,000 VACCINATIONS. Over 175 individuals have been a part of the LSUHS vaccine teams comprised of physicians, nurses, nursing, medical and allied health students, and the Louisiana National Guard.

KTBS3 -  As mask mandates are lifted across the state, the medical community is waiting to see what effects may come from the decision. Dr. John Vanchiere, an infectious disease expert at LSU-Health Shreveport, said overall, he thinks that it was the right decision. 

KTAL/KMSS -  Shreveport doctors are urging the public to not underestimate COVID-19 as Governor Edwards has lifted the state’s mask mandate for at least the next four weeks. Dr. Andrew Yurochko with LSUHS says the virus spread has followed a pattern and therefore, one must continue to protect him or herself.

A new variant of COVID-19 has been identified in Louisiana by scientists at the LSU Health Shreveport Emerging Viral Threats Center. LSUHS announced this month that the B.1.630 variant had been sequenced and reported by the center, though health officials believe this variant's predominance is very low and much less transmissable than the deadly delta variant.

KTBS3 - Dr. John Vanchiere, an infectious disease and pediatrics specialist with LSUHS said some of the conditions that do not compromise the immune system, but make a person eligible for a booster shot include obesity, diabetes, heart disease and an age over 65.

KSLA12 - “We can do it. We know there is no reason why we can’t do it. Most of the people who have been hospitalized or have severe disease now have not been vaccinated. We know that getting vaccinated reduces the likelihood that you end up in the hospital, at least 25-fold,” said Former State Representative Barbara Norton.

KSLA12 - “What we tended to see with the Delta variant is it has impacted our pregnant populations very very hard, especially at the height of the Delta variant we had transfers from all over the state of pregnant woman who were in respiratory distress and significantly decompensating,” said Dr. Caitlin Busada, associate program director of residency of Obstetrics & Gynecology at LSUHS.

The EVT Viral Genomics and Sequencing Lab at LSU Health Shreveport is first in the state to sequence and report that a new variant of SARS-CoV-2, the virus that causes COVID-19, has been detected in Louisiana. The new variant, B.1.630, was sequenced last week from two samples collected in Baton Rouge.

A new CDC report finds that U.S. adults reported experiencing increased anxiety and depression symptoms during August through December 2020 as new COVID-19 cases increased. Find strategies to help cope with stress during COVID-19 and how to get help if you’re struggling.

KTBS3 - Dr. John Vanchiere, the lead investigator in the Pfizer vaccine study at LSUHS said, “We expect that to take at least four to six weeks of time. And Pfizer and Moderna are both starting additional enrollment in the pediatric studies in that 5- to 11-year-old age range, so that they can get more data under the research protocol to submit to the FDA when it’s appropriate.”

LSU Health Shreveport has been on the front line fighting the COVID-19 pandemic since the beginning. The establishment of the Emerging Viral Threats lab in March of 2020 led to mass testing and vaccination sites, clinical trials in patient treatment options and viral sequencing that discovered 7 COVID-19. variants.

KTBS3 - Dr. John Vanchiere, an infectious disease and pediatrics specialist and the lead investigator on the Pfizer vaccine study at LSU Health Shreveport, shares "Demonstrating effectiveness that is preventing hospitalization and death or severe disease is very challenging in the pediatric population, because kids don't get generally very sick."

Wall Street Journal - Some virologists believe the Delta variant evolved to maximize transmissibility and that its ability to spread rapidly will eventually reach a ceiling as more of the global population gets vaccinated. “It looks like this virus is already driving a Lamborghini right now in terms of transmissibility, so I’m not sure it can get much faster,” said Jeremy Kamil, a virologist at LSU Health Shreveport who is studying coronavirus genetics. Read the full article.

Forum - Dr. Sarwat Umer, Associate Professor of Medicine/Pediatrics, and Dr. Anusha Vuppala, Rheumatology Fellow, at LSUHS share information on Multisystem Inflammatory Syndrome in Children (MIS-C), a complication associated with COVID-19 infection in children.

KTAL/KMSS - “It seems that we’re past our peak of this delta variant surge,” said LSUHS Professor Dr. John Vanchiere. “Most of the rest of the nation is still in the climbing phase of this delta surge, so we’re a few weeks ahead of many places in terms of, our numbers seem to be slowing down on hospitalization side.”

KTAL/KMSS - “By November 1st, if people are not vaccinated then they would not be able to work inside of the various Ochsner facilities,” says Dr. Charles Fox, the chief medical officer at Ochsner LSU Health. 

LSU Health Shreveport is looking for Part-time / Temporary workers for their COVID-19 Strike Team. Swab Assistants are needed for Shreveport-Bossier, as well as Monroe, Ruston, Alexandria and Lake Charles areas.

SCIENCE.org - Dr. Jeremy Kamil, Associate Professor of Microbiology and Immunology at LSU Health Shreveport, says "that we truly have no idea what mutations will show up next, in what order, or on top of what existing variants."

KSLA12 - “PCR is the gold standard, but people who are nervous, they have a cold, runny nose or fever, it’s a great way to sort of test,” said Dr. Andrew Yurochko, professor and vice-chair of microbiology and immunology at LSU Health Shreveport.

KTBS3 - “What I recommend for most people, especially if they've had symptomatic COVID, is that they wait about a month, six weeks, somewhere in that range before they get their first dose of vaccine,” Dr. John Vanchiere, LSU Health Shreveport.

ABC4 - “We do not know whether this is going to be better or worse than Delta, there’s not enough information,” Dr. Andrew Yurochko with LSU Health Shreveport tells NewsNation. “Forty-four states have reported Lambda cases and WHO has labeled it “a variant of interest.”

AAMC.org - Despite more than 70% of adults in the country having received at least one COVID-19 vaccine dose and 81% of people 65 and older being vaccinated, a dramatic spike in infections among unvaccinated younger people, coupled with staffing shortages, is testing the surge plans hospital systems developed for previous waves.

FDA.gov - The U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older.

LA Radio Network - “Those who have been hesitant to take this as a very important milestone that should allow them just to breathe a sigh of relief and go get their vaccine,” said LSUHS Infectious Disease Specialist Dr. John Vanchiere.

StatNews - By cutting how much the virus replicates — both through preventing infections and by shortening the infections that do occur — vaccines limit the likelihood of additional, more dangerous variants. Says Jeremy Kamil, a virologist at LSUHS, “The virus has to replicate in order to mutate, but each virus doesn’t get many lottery tickets in a vaccinated person who’s infected.”

BBC - Dr, Jeremy Kamil, a virologist at LSUHS, says "I would be delighted that a vaccine company overcame the immense challenges to make it work. But it's imperative that the efficacy data be vetted independently."

KEEL - Dr. John Vanchiere, LSUHS Pediatric and Infectious Disease Specialist, explains, "Booster shots are recommended for individuals who are moderate to severe immune-compromised. It's the same vaccine, just like the second dose, you're going to get a third dose of the same thing."

The Guardian - Dr. John Vanchiere, a professor of pediatrics and infectious diseases at LSUHS, shared that caring for seriously ill children is always distressing, but more so when “we know the vast majority of these infections are preventable." 

Cape Cod Times - “I would say (the road race) is probably minimal risk” for the spread of the novel respiratory virus,” said Jeremy Kamil, PhD, associate professor of microbiology and immunology at LSUHS, where he leads COVID-19 genomic sequencing. “It’s a lot of people running, breathing hard, but they’re breathing outside. The ventilation factor is enormous.”

KSLA - Emerging data have demonstrated that immunocompromised people who have low or no protection following two doses of mRNA COVID-19 vaccines may have an improved response after an additional dose of the same vaccine. No appointments are necessary to get the additional shot, but LSUHS suggests you come based on a schedule shown here.

Baton Rouge - The Louisiana Chapter of the American Academy of Pediatrics sent a letter to Gov. John Bel Edwards stating that the 750 member organization strongly recommends universal masking while indoors in schools.

KTBS - With children headed back to school during yet another COVID-19 surge, many parents of young children are wondering when those under age 12 will be able to get vaccinated. Dr. John Vanchiere, lead investigator on Pfizer vaccine trials at LSUHS, said the hospital is seeing an increase in vaccinations for the 12-18 age group. As for kids ages 5-11, the trials are ongoing and expanding.

Heavy.com -  Dr. Jeremy Kamil, Associate Professor of Microbiology and Immunology at LSUHS leads COVID-19 sequencing at the institution shared that he believes a doomsday variant is extremely unlikely and that people should be talking instead about the importance of getting vaccinated because variants can develop when large numbers of people do not.

Dr. John Vanchiere, Professor of Pediatrics and Infectious Disease at LSUHS served as was one of eight clinical leaders in Louisiana invited to participate in The Louisiana Community Engagement Alliance Against Covid-19 Disparities (LA-CEAL) Town Hall meeting which was designed to provided updated information on COVID-19.

KNOE - Dr. Shawn McNeil, Assistant Professor of Psychiatry and Behavioral Medicine at LSUHS says mental health is as important and in some cases more important than a person’s physical health. He says some children are going through a lot of stressful events right now. including their sleep schedule changing, more expectations in a new grade level, or the pandemic, including mask mandates.

KSLA12 - Louisiana Gov. John Bel Edwards has implemented a statewide indoor mask mandate to combat the spread of COVID-19 and the delta variant of the virus. Gov. Edwards made the declaration during a news conference Monday, Aug. 2. The new mask mandate is set to expire on Sept. 1, 2021, but could be extended if needed, the governor said.

KTAL/KMSS - LSUHS was awarded one of three contracts in Louisiana to deliver FREE COVID-19 testing in kindergarten through twelfth grade (K-12) for the 2021-2022 school year. The agreement is in partnership with the Louisiana Department of Education (LDOE) and the Louisiana Department of Health (LDH) with funding provided by the Center for Disease Control (CDC).

KTAL - Dr. Yurochko, a Professor and Vice-chair of Microbiology and Immunology at LSU Health Shreveport, said by now one ought to know that “masks absolutely work” — and his stance on it is abundantly clear, citing Delta variant is more infectious and anyone who is more vulnerable or who has underlying health issues should mask up.

New York Times - Facing deep mistrust stoked by rampant conspiracy theories, local health officials are fighting for influence when the only sure strategy for beating back the virus is getting more people vaccinated. “It’s a lot of small battles in different places,” Dr. John Vanchiere said, “and every battle is going to be different.”

Boston Globe - Dr. Jeremy Kamil, an associate professor of microbiology and immunology at LSUHS, oversees a team of scientists reading the genomes of positive virus samples each week. A run of samples this week found the number of cases involving the delta variant had exploded. Dr. John Vanchiere, a professor of infectious disease at LSUHS said a growing public awareness of local delta cases was one reason his team was now vaccinating twice as many people as a month ago — as many as 100 a day.

LSUHS hosted a press conference where research experts, medical professionals and community leaders gave an update on the COVID-19 pandemic and the emergence of the new Delta variant of the virus, along with latest numbers and efforts to increase vaccination rates.

Local clergy and Vaccination providers, including LSU Health Shreveport, are joining forces to administer free Pfizer, Moderna and Johnson & Johnson vaccinations to all citizens with particular emphasis on teenagers.  Also, other health screening services will be offered including blood pressure checks, COVID-19 Rapid Test, glucose/blood sugar check and physical fitness activities for the whole family.

Bloomberg News - Given the patchy start to COVID surveillance last year, some experts have expressed concern over whether the CDC can create a system that will help bring the pandemic to a true end. Jeremy Kamil, a virologist at LSUHS, points out that the agency takes weeks to provide data from sequencing including diseases such as influenza, too.

KSLA 12 - On Monday, July 19, the American Academy of Pediatrics suggested all kids age 2 or older should wear a face mask. “The ages 12 and under, they are a vulnerable population and the argument from the AAP that wearing mask in schools will help lessen the risk of transmission and infectivity for those, I think is a very strong argument,” said Thomas.

KSLA 12 - Dr. Jonathan Eaton, a critical care doctor with LSUHS shares his main concern during this latest surge in COVID-19 cases is the new age group being impacted. “The best thing we have is being vaccinated. Don’t think because your 30 to 40 years old you’re invincible to this.”

KEEL Radio - LSUHS Dr. John Vanchiere talks about the medical community's growing concern over the new COVID Delta variant. "We've gone from a hundred cases a day to over twelve hundred cases a day," he says, addressing the increase across the state, "We're seeing a lot more infections now, locally as well as statewide. It's a big surge in infections."

Boston 25 News - Dr. Jeremy Kamil, an associate professor of microbiology and immunology at LSU Health in Shreveport, Louisiana, calls the two-dose data very clear and very strong. “You can control your behavior and go back and get that second shot and do your part to protect our community and to protect our country from the pandemic having another big wave here."

KTBS 3 - Dr. John Vanchiere, an infectious disease specialist and the principal investigator in the Pfizer vaccine study at LSU Health Shreveport, said they are now in the 10th month of the initial clinical trials and no booster is needed so far. “So our current look is that for the vast majority of people, boosters are not on the horizon, at least for the first year after injection.”

KTAL/KMSS - COVID-19 Pfizer vaccinations were provided by LSUHS at St. Mary of the Pines Catholic Church. There were no out-of-pocket costs, and no one was turned away based on their insurance status as their main priority is keeping the community safe.

KTBS 3 - A mobile vaccination effort continued at the Renaissance of Allendale Apartments. This was a collaborative effort of multiple agencies: City of Shreveport, HUD, Department of HHS, LSU Health Shreveport and Shreveport Housing Authority. "The way that we combat that virus, the way that we get back to normalcy is through being vaccinated and I do not want us to let our guard down," said Shreveport Mayor Perkins. 

BBC World - Even with 166 examples of Delta plus shared on GISAID, "we don't have much reason to believe this is any more dangerous than the original Delta," according to Dr Jeremy Kamil, a virologist at LSU Health Shreveport. "Delta plus might have a slight advantage at infecting and spreading between people previously infected earlier or who have weak or incomplete vaccine immunity."

NOLA.com - “This virus can get past the defenses that our bodies made against earlier pandemic viruses,” said Jeremy Kamil, a virologist who has been sequencing variants at LSU Health Shreveport. Being infected last summer will not necessarily protect someone from being infected by the delta variant.

Louisiana Radio Network - LSU Health Shreveport infectious disease professor Dr. John Vanchiere said cases have been the highest amongst men under the age of 18. “The cases that have been reported in-depth on, about 400 cases, they have said that all of those who’ve been effected have recovered.” (image from Amelia Heart & Vascular Center)

Nature - The rapid rise of the highly transmissible strain in the United Kingdom has put countries in Europe, North America and Africa on watch. Jeremy Kamil, a virologist at LSU Health Shreveport, expects Delta to eventually become dominant in the United States, “but to be somewhat blunted by vaccination”.

KSLA 12 - Across Louisiana, more than 3 million doses of the vaccine have been placed in arms, while 1.4 million Louisianans are fully vaccinated — about 32% of the state. “The faster we can vaccinate ... the more difficult it is for these variants to emerge across the world, and we are seeing it,” LSUHS Dr. John Vanchiere said.

Louisiana Radio Network - The objective of the grant is to strengthen global capabilities to detect and respond to pandemic threats in the future. Director for Emerging Viral Threats at LSUHS Dr. Andrew Yurochko said the award is indicative of LSU Health Shreveport’s strides in detecting variants and assisting with vaccine rollout.

Red River Radio - Work by Drs. Jeremy Kamil and Rona Scott along with COBRE principal investigators Drs. Andrew Yurochko and Chris Kevil has produced and shared 2,839 full coverage SARS-CoV-2 genomes, which amounts to over 60% of the SARSCoV-2 genome surveillance from Louisiana, and 1.2 % of the total US data submitted to GISAID which is the Global Initiative on Sharing All Influenza Data.

The Rockefeller Foundation - LSU Health Shreveport (LSUHS) is receiving funding ($340,000) from the Rockefeller Foundation. This follows the announcement yesterday of LSUHS being awarded $730,000 to further its work in genomic sequencing of COVID-19 through a NIH supplemental grant.  LSUHS joins Harvard and the Broad Institute at MIT among others in the US Regional Accelerators for Genomic Surveillance.

New York Times - The split is particularly stark in Britain, which is facing the spread of a new variant, while America has essentially lifted all rules for people who are vaccinated. “Globally, it’s a nightmare, because most of the world is still not vaccinated,” said Jeremy Kamil, a virologist at Louisiana State University Health Shreveport. “It raises the stakes.”

KTBS 3 - Dr. Jeremy Kamil from LSU Health Shreveport joins the discussion about the latest on the vaccine, variants and the state of our region.

LSU Health Shreveport has identified two cases of the novel COVID-19 variant of concern, B.1.617.2, which was first identified in India and is rapidly spreading around the world. LSU Health Shreveport sequencing also reveals that B.1.1.7, sometimes called “the U.K. variant,” remains dominant in North Louisiana, as is the case in the rest of the United States, as well. 

KTAL/KMSS - Health officials from LSUHS say long COVID is something people have been experiencing after recovering from COVID-19. Symptoms like fevers, cold-like symptoms, and extreme fatigue can appear weeks after infection.

Daily Iberian - "What we know is that people who were vaccinated, if they do get sick, if they catch COVID, their symptoms are generally mild, and the amount of virus in their nose is generally less,” said Dr. John Vanchiere, infectious disease and pediatrics specialist at LSU Health Shreveport.

ArkLaTex Homepage - “Why the second shot is so important, is the first one gives you a good response, the second one is better, and the third one gets even better and better and better. And so it just primes your immune response,” Dr. Andrew Yurochko, professor of microbiology and immunology at LSUHS said.

Blue Mountain Eagle - Dr. Jeremy Kamil, an associate professor of Microbiology and Immunology at LSU Health Shreveport, said it is crucial to be mindful of “over-interpreting” the emergence of a variant. Virus variants are a significant public health concern, but viruses continually change.

Los Angeles Times - Scientists have found that the coronavirus that causes COVID-19 is capable of infecting two types of brain cells — neurons and astrocytes. Scientists have been trying to understand why and how it causes these issues in the brain, said study leader Diana Cruz-Topete, a molecular endocrinologist at LSU Health Shreveport.

China Daily - "Despite a few mutations here and there, the virus is still SARS-CoV-2 and the disease is still COVID-19. Risk will be highest to the elderly, and to those in high-risk groups, such as people who are diabetic, overweight, (have) high blood pressure, or who have inborn errors of immunity," warned Dr. Jeremy Kamil, LSUHS associate professor.

In a collaborative event between LSUHS and LA Tech University, Dr. Chris Kevil, Vice Chancellor for Research at LSUHS, and Theresa Sokol, MPH, Acting State Epidemiologist for the Louisiana Department of Health opened the year with New Frontiers in Biomedical Research lectures focused on patient care.

The74Million - “Until you get upwards of 80 percent of children vaccinated, you’re going to have a hard time going back to pre-pandemic practices without some risk of illness and death,” Jeremy Kamil, associate professor of microbiology and immunology at Louisiana State University Health Shreveport, told The 74.

KTBS - Dr. John Vanchiere, lead investigator on the Pfizer vaccine study at LSUHS said, “The vaccine is effective at several things. Number one, reducing people from getting sick from COVID and spreading it to other people. Big time important is that vaccination reduces hospitalization and death.”

LSU Health Shreveport continues COVID-19 testing, while simultaneously offering large scale vaccine clinics and leading Louisiana in sequencing the virus from positive test samples. Testing and vaccine sites are located throughout Northwest Louisiana—including Minden, Monroe, Ruston and rural outlying cities like Tallulah. A concerted effort has been made to deliver testing and vaccines regardless of the ability to register or travel far outside of one’s home as “access for all” has been a guiding principle for the delivery these services.

CNN News 18 - India recorded on Monday 3,52,991 new Covid-19 cases and 2,812 deaths in the last 24 hours. The country saw 22.5 lakh new infections in the last one week, the highest ever the world has seen, pushing India’s health infrastructure to a brim.

BoomNews India - Number of COVID-19 cases in India is now at the highest per day in any country in the world. Dr. Jeremy Kamil, LSUHS virologist, discusses status of variants, vaccines, and transmissability.

KPVI 6 News - "A bit of low-grade fever, or muscle aches, fatigue for a couple of days, even headaches after getting your vaccine are not uncommon,” states Dr. John Vanchiere, the lead investigator on the Pfizer vaccine study at LSU Health Shreveport. “That’s an indicator that your immune response is kicking in."

BBC News - A coronavirus variant identified in India is being investigated by scientists across the world. However, it is not yet known how far it has spread or whether it is driving the deadly second wave of Covid in India itself. Dr Jeremy Kamil, a virologist at LSUHS, says, "I doubt whether the Indian variant is more infectious than the UK variant - and we must not panic."

Pitt News - “A variant is like a unique constellation of mutations while a mutation will be like one star in that constellation,” stated Jeremy Kamil, virologist at LSU Health Shreveport. “Alternatively, if a variant was a fingerprint, then a mutation will be one line that’s part of the fingerprint.”

NBC News - Jeremy Kamil, a virologist at LSU Health Shreveport, said that he wasn’t surprised this mutation was detected, as lab data suggests it would play a role in breakthrough cases.

KEEL 101.7FM - The local medical community has stepped up on several fronts to battle COVID-19 on the front lines and in the lab. The Commission has approved the donation of as much as $1 million dollars for the Center for Excellence for Emerging Viral Threats (CEVT). This money will be used for a new building to expand the local medical school and for continued research.

KTBS 3 - "Those who are hesitant, and I would say that's the vast majority ... those who are hesitant, than refusing ... will see very quickly that their colleagues have gotten the vaccine and no adverse side effects or long term complications or other issues," said Dr. John Vanchiere of LSU Health Shreveport.

BBC.com/Russia - Scientists from the United States and Argentina came to this conclusion after analyzing the neutralizing ability of the sera of those vaccinated with the Russian vaccine. But Sputnik still protects against a severe form of the disease, the authors emphasize.

KTBS 3 - It's been difficult for much of the homeless to get to sites like the Louisiana State Fairgrounds. That's why Dr. John Vanchiere, an infectious disease specialist with LSU Health Shreveport, looked at all options, even transportation to get the homeless population there.

KSLA12 - LSUHS Dr. John Vanchiere said as a country we have a long history of producing vaccines and it’s normal for manufacturing issues to occur. The fact that it’s recognized and there’s a transparency to the reporting should give us even more trust.

KSLA 12 - “If you can minimize the spread in the group that’s spreading it the most, you, of course, dramatically drop the infection rate,” explained Dr. Andrew Yurochko, a professor in LSU Health Shreveport’s microbiology and immunology department.

Newsweek - Virus samples showing up with multiple mutations is not uncommon, and two mutations is not a lot, according to Jeremy Kamil, a virologist at Louisiana State University Health Shreveport.

“There are still folks who are still a little nervous that the vaccine was produced in a relatively short length of time think the important thing to note here is the technology is not new while the vaccine is the technology is something, we’ve been working on for decades,” Dr. John Vanchiere shares.

Nature.com - Ramped-up sequencing efforts are helping to identify mutations that might boost transmission or help a virus evade immune responses. For the scientists who have spent the past year poring over hundreds of thousands of coronavirus genomes, the United States has been an enigma.

“LSUHS is adjusting our strategy to accommodate more folks,” Dr. John Vanchiere said. “I would like to see longer lines and more people there getting vaccinated. And we have (the) capacity to vaccinate more than 2,000 or 2,500 people per day.”

NBC CT - LSU Health Shreveport Virologist Jeremy Kamil told NBC Connecticut Investigates that halting their spread will require other measures. Kamil was among a team of researchers that discovered seven new COVID-19 strains, known as "variants," aside from the variants first identified in the UK, South Africa, and Brazil. 

Dr. Suzanne Tinsley, Associate Professor of Physical Therapy at LSU Health Shreveport, was interviewed by the Simple Church radio broadcast in Shreveport, LA and shared information on COVID-19 recovery. 

Louisiana Radio Network - LSU Health Shreveport Chief of Hospital Medicine Dr. Mike Sewell said the current case fatality rate is far lower than it was this time last year when, according to one study last year, it was as high as four percent in New Orleans. He estimated we’re closer to one in one thousand cases.

To date, LSU Health Shreveport has administered over 48,000 vaccines as the first large-scale vaccine clinic in Louisiana. In order to accommodate those who work standard hours throughout the work week, and to maintain the health and wellbeing of our staff and volunteers, several changes are being made to the vaccination schedule moving forward. 

NBC News - "There are certain variants that are more transmissible, and we have strong data on that, but the thing people should take away from the variant story is just: Don't let your guard down," said Dr. Jeremy Kamil, an associate professor of microbiology and immunology at Louisiana State University Health Shreveport.

Thousands in northwest Louisiana have been vaccinated for COVID-19. Positivity rates have gone down in recent weeks. Deaths from the virus have also slowed. Is the end of the pandemic near?

Four thousand three hundred (4300) doses of the Johnson and Johnson COVID-19 vaccine will be available during the twelve-lane vaccination clinic to be held at the Brookshire Grocery Arena located at 2400 Century Link Center Drive from 9:00 a.m. to 4:00 p.m.

KTBS3 - As more and more coronavirus vaccines becomes available, it's becoming clear that a lot of people don't want it. Whether it's reluctance, hesitancy or flat out refusal, a huge percentage of Americans are not interested in getting a COVID-19 vaccine, according to surveys.

KSLA12 - According to the CDC, medical experts are still working to learn whether or not the vaccine slows transmission rates, even if you don’t get sick. That’s why, for now, even after you get the vaccine, you are urged to continue behaviors that are proven to slow the spread of the virus.

Baton Rouge Advocate - In Shreveport, LSUHS - in partnership with Christus Shreveport-Bossier Health and Willis Knight Health System - had been doing about 1,500 shots a day at a drive up community vaccination site. That was shut down Monday because of the storm, said LSUHS spokesperson Lisa Babin, and won’t resume until next week.

We are proud to announce that on February 24, 2021, 2:00 PM – 3:30 PM EST Dr. G.E. Ghali, Chancellor for LSU Health Shreveport has been invited to be part of a panel of four people on one of the Town Hall Sessions on the topic of Building Bridges between Public Health and Healthcare Systems to Ensure Equitable Vaccination.

Popular Science - A new preprint study suggests that last year’s Mardi Gras celebrations were responsible for roughly 50,000 COVID-19 cases across the state.

Governor John Bel Edwards visited Louisiana’s first mass community vaccine clinic to see firsthand just how well the community effort involving LSU Health Shreveport faculty, students and staff, Region 7 Office of Public Health, Louisiana National Guard, BPCC nursing students, CHRISTUS Shreveport-Bossier Health System and Willis-Knighton Health System is working

Shreveport Times - Dr. John Vanchiere, professor and chief of pediatric infectious diseases at LSUHS, talked about the benefits of getting the vaccine and its safety. “We know that early on when people get infected with COVID-19, most people have no symptoms at all and that is one of the very critical features of this type of infection compared to influenza."

KSLA's Christian Piekos asked our local healthcare heroes to write a reflective letter to their 'pre-pandemic' selves highlighting the unthinkable challenges they'd face responding to the pandemic. (You have to be logged in to Facebook to watch the video.)

KTBS-3 - The Center of Excellence for Emerging Viral Threats at LSU Health Shreveport plays a big role in COVID-19 testing and community vaccinations. But another important role it plays involves the identification of COVID-19 mutations and the variants they cause.

KTBS3 - While most Americans are still waiting to get the COVID-19 vaccine, some moms-to-be are worried about possible side effects to their unborn children.

KSLA12 - Extended interview with Dr. Andrew Yurochko, Professor and Carroll Feist Endowed Chair of Viral Oncology and Department Vice-Chair of Microbiology and Immunology

KTBS 3 - “The quicker that people get vaccinated, the less chance of any virus being around and given the opportunity to mutate,” Dr. Ghali, LSU Health Shreveport Chancellor explained. “The longer a virus is around, the longer they're going to be able to mutate. It's a natural course in the development of the virus.”

KSLA12 - According to professor and pediatrics chair Dr. Maroun Mhanna, the COVID-19 vaccine takes about one week to 10 days to become effective. Therefore, it is still possible to test positive for the virus, even after getting the vaccine. Also, in order to ensure maximum effectiveness, it is important to get both doses of the vaccine.

Fortune.com - Even the type of sequencing done in the U.S. has been lacking, some experts say, with much of the effort focused on finding cases of the U.K. variant, rather than casting a wider net for any variant, including ones not previously identified, said Jeremy Kamil, a virologist at Louisiana State University Health Shreveport.

Bloomberg.com - Even the type of sequencing done in the U.S. has been lacking, some experts say, with much of the effort focused on finding cases of the U.K. variant, rather than casting a wider net for any variant, including ones not previously identified, said Jeremy Kamil, a virologist at LSU Health Shreveport. “It’s the Wild West,” he said. “Every state, city, county is doing its own thing. It’s a bunch of random cats and no one is trying to herd them.”

Shreveport Times - LSU Health Shreveport's Dr. Jeremy Kamil talks about the importance of genome sequencing during COVID-19.

This week LSU Health Shreveport took a historic step towards stopping the spread of the coronavirus. In addition to continuously testing for COVID-19, the Emerging Viral Threat Lab has now organized the distribution of the vaccine to individuals age 70 and up. On the first day of testing, over 1100 seniors were able to get the vaccine from the safety of their vehicles.

Bossier Press - Louisiana Governor John Bel Edwards extended the current Phase 2 coronavirus restrictions on Tuesday at a press conference for another 21 days as COVID-19 metrics remain high in the state ahead of Christmas.

As it relates to COVID, each of us will make a choice about the vaccine. I choose to be vaccinated because I have seen the complications of COVID close up and have great faith in the scientific trials supporting this vaccine.

Bloomberg - On Monday, John Vanchiere, the principal investigator for a trial site at LSU Health Shreveport, emailed 245 participants to let them know the COVID-19 vaccine trial would be slowly unblinded. By Wednesday afternoon, seven placebo recipients got their first shot, all of them health-care workers.

KSLA 12 - Dr. Robert Rhoads, professor and emeritus chairman of the Department of Biochemistry and Molecular Biology at LSU Health Shreveport, developed key components of the mRNA over years of work. The vaccine uses messenger RNA, or mRNA, which essentially provides instructions to the body on how to fight the novel coronavirus.

KSLA 12 - “It is gratifying to see LSU Health Shreveport’s contributions to the Pfizer-BioNTech vaccine through licensing of a LSUHS patent to BioNTech for mRNA-stabilizing cap analogs and in serving as the only north Louisiana vaccine trial site. Additionally our numerous COVID-19 clinical trials are providing access to novel therapies reflecting the benefit of having an academic medical center in our community,” shared Dr. G.E. Ghali, Chancellor of LSU Health Shreveport.

KSLA 12- “If the EVT Lab had not existed, quite frankly, I think we’d be in a much darker place here in the northern part of the state,” said Dr. Chris Kevil, vice chancellor of research and one of the leading minds behind creation of the lab. “The EVT Lab has been fundamental in our ability to monitor COVID infections in patients out in this community."

KTBS3 - Ahead of the upcoming holidays, Dr. John Vanchiere of LSUHS, says it is reasonable to get tested prior to attending any gatherings and travel. But says it is best to avoid gatherings all together.

Arklatex Homepage - Chancellor Ghali shares steps to take to stay safe during the holidays.

Lisa Strahan Babin, Executive Director of Communication, Public Affairs and Development, shares how LSUHS has responded to the 2020 challenges in bountiful ways.

Forum News - Marie Vazquez Morgan, PT, PhD, clinical associate professor of physical therapy at LSUHS shares to eat whole nutritious foods, move more, decompress and catch up on your sleep.

Dr. John Vanchiere, professor of pediatrics and infectious disease at LSUHS, shares how many adults have too dramatic an immune response to coronavirus.

Dr. Ghali speaks with KEEL Radio host, Robert J. Wright about COVID-19 symptoms and what to anticipate.

According to Sharon Dunn, the dean of LSU Health Shreveport’s School of Allied Health Professionals and the president of the American Physical Therapy Association, chronic fatigue is one of the aftereffects of COVID-19 on some patients.

Dr. John Vanchiere, professor of pediatrics and infectious disease at LSU Health Shreveport, stresses that now, more than ever, people should get a flu shot. Particularly if they are around children.

MSN.com - The Emerging Viral Threat (EVT) Lab at LSU Health Shreveport has now sequenced a total 651 Louisiana SARS-CoV-2 virus genomes making it the largest contributor to date of genetic data on SARS-CoV-2 in the state. 

The Emerging Viral Threat (EVT) Lab at LSU Health Shreveport has now sequenced a total 651 Louisiana SARS-CoV-2 virus genomes making them the largest contributor to date of genetic data on SARS-CoV-2 in the state. SARS-CoV-2, which is short for ‘Severe Acute Respiratory Syndrome Coronavirus-2,’ is the virus that causes COVID-19, and viral genome sequencing is contributing to a worldwide effort to fight the ongoing pandemic.

KTBS 3 - Andrew Yurochko, Professor of Microbiology and Immunology at LSUHS, shares, “When you think about total tests, 0.1% of the total tests of the entire country are done right here in Northwest Louisiana, where we’ve focused on our own citizens, not just in Shreveport or Caddo Parish, but in all of Region 7 which is Northwest Louisiana.”

The Bossier Chamber of Commerce honored “Patriots of the Pandemic” to recognize those in the community who played key roles in fighting back the pandemic. LSU Health Shreveport’s COVID Surveillance Strike Team received a special Eagle Award for testing coordination inside nursing homes.

The Emerging Viral Threat Lab at LSU Health Shreveport has processed over 110,000 COVID-19 test samples from multiple public health regions of the state and created over 170,000 test kits which were distributed throughout the state during its first six months of operation.

LSUHS is expanding enrollment in the Pfizer-sponsored COVID-19 vaccine study for the next two weeks to include individuals ages 16-18 and those older than 85 years of age.  Those interested in participating in this important vaccine trial should sign up as quickly as possible.  

Shreveport Times recaps the past 6 months with COVID-19 and talks to LSU Health Shreveport's Dr. Chris Kevil about what the next 6 months will entail with vaccine development.

KTBS 3 - LSU Health Shreveport announced this week that it is participating in the Pfizer COVID-19 vaccine study and is currently enrolling people to participate.

Health Matters host, Dr. Sanford Katz, was  joined by LSUHS's Andrew Yurochko, PhD, Professor of Microbiology and Immunology and Carroll Feist Chair of Viral Oncology and Dr. John Vanchiere, Chief of the Department of Pediatrics Infectious Diseases. to discuss testing, treatments and vaccines for COVID-19.

The state's peak in April came mostly from widespread infections in New Orleans. Now the rest of Louisiana is surging, reports William Taylor Potter and Michael Stucka, Lafayette Daily Advertiser and USA TODAY.

Chancellor Dr. G. E. Ghali spoke at the COVID-19 press conference  about the recent rise in COVID-19 cases in Louisiana, the EVT Lab and testing in North Louisiana and the importance of wearing masks.

The Daily Beast - "Louisiana is getting pummeled by the virus. But without a comprehensive early testing program in Shreveport, it would have been worse still."

Griggs Enterprises and McDonald's has been providing lunch for several months. Their generosity during this time is so appreciated by our team members, who are working around the clock in response to the COVID-19 pandemic.

The number of hospitalized COVID-19 patients in NW Louisiana has increased in recent weeks. Our teams are rising to this challenge with incredible compassion and professionalism; however, we need your help. 

Dr. Keith Scott spoke with KTBS about the recent spike in COVID-19 cases and whether wearing a mask really helps.

Amid the coronavirus pandemic and stay at home orders, alcohol sales surged. Dr. Nicholas Goeders was on Red River Radio's Health Matters June 25 to talk about how the pandemic has affected alcohol and substance abuse addictions.

Congratulations to Dr. Arrigo De Benedetti, Professor of Biochemistry and Molecular Biology, and Dr. Nadejda Korneeva, Assistant Professor of Emergence Medicine, who have been awarded an intramural COVID-19 grant in amount of $50,000.

There are more than 7,500 positive cases; more than those in the 60 to 69 age range, where there are close to 6,900 cases. LSUHS Chancellor Dr. G.E. Ghali said it could be due to more testing. But he says this age group is also less likely to practice social distancing.

Girlology wants to help your family avoid COVID 19 this Summer with practical tips from LSUHS Pediatric Infectious Disease expert Dr. John Vanchiere (AKA: Dr. Germ).

Shreveport Times - From the formulation of an emerging viral threat lab to community testing, LSU Health Shreveport has actively fought COVID-19. Dr. Chris Kevil talks about testing, clinical trials and prevention.

Rick Rowe, KTBS-3 News, talks to EVT Lab scientists and researchers at LSUHS about the work they are doing that is saving lives.

"The stress and fear associated with the COVID-19 pandemic will result in unprecedented increases in drug and alcohol use among our friends, our families and others in our communities," states Dr. Goeders, Executive Director of the Louisiana Addiction Research Center.

Nextstrain reports new sequences from Belgium (19), Italy (12), Uganda (20) and the USA (95). The 95 new Louisiana sequences, provided by the LSUHS EVT Lab are shown together with older samples from Louisiana.

"The funding provided by the Committee of One Hundred is essential for the EVT Lab to continue the costly endeavor of conducting antibody/serology testing, making testing kits, and processing of COVID-19 tests,” shared Dr. G.E. Ghali.

“Our unique team of women made the vision for the EVT Lab a reality. They are the true beating heart of the lab,” said Andrew Yurochko, PhD “Without them, there is no way this would be possible. As a group, they have worked the longest and hardest hours. They are really the superheroes.”

The Lions Club District 8L received a grant from the Lions Club International Foundation that has resulted in a donation to the Emerging Viral Threat (EVT) Lab at LSU Health Shreveport.

KTBS 3 - “What makes this so exciting is not only are we on the forefront, we are on the forefront of the forefront,” said Dr. Keith Scott, the principal investigator for the trial at LSU Health Shreveport. This is not the first time inhaled nitric oxide has been used to fight a coronavirus. It was used in 2004 during the SARS outbreak.

LSU Health Shreveport is now one of five sites in the world and the first in Louisiana involved in a clinical trial that assesses inhaled nitric oxide as a treatment for patients with mild to moderate cases of COVID-19.

"As a result of a lot of sacrifice by our community, including importantly the business sector, the number of new cases, hospitalizations and patients needing (help) for COVID-19 is declining," shared Chancellor Ghali.

The LSU Health Shreveport Foundation has received a $10,000 gift from the U.L. Coleman Companies to support the effort to provide COVID-19 testing to first responders in north Louisiana.

St. Mary Medical Center will now be able to accommodate inpatient pediatric, labor and delivery, Neonatal ICU and Pediatric ICU patients. This move will allow the hospital system to add 100 more beds that’s part of their ICU expansion to mee the need for COVID-19 patients.

We are very appreciative of this generous gift from Mr. Organick and Inferno Manufacturing Corp. It will be put to invaluable use in expanding the access to both viral and antibody testing, particularly in underserved areas of north Louisiana,” stated Chancellor Ghali.

A mobile COVID-19 testing lab for medically underserved citizens began visiting sites across Caddo Parish this week, thanks in part to a partnership with LSU Health Shreveport and the Caddo Parish Commission.

Dr. Andrew Yurochko shares that in some areas of NW Louisiana, Feist-Weiller's "Partners in Wellness", while focused on mammography and other cancer screening, also provided the only health care available. Now, the program’s three vans offer testing for COVID-19.

Ochsner LSU Health Shreveport will offer COVID-19 Antibody Testing to healthcare workers in North Louisiana. Beginning this week the test will be available to more than 3,700 employees, and 1,400 physicians and residents.

WBRZ News - “We know a lot of these things work, we just don’t know when they work the best. And that’s what we’re trying to figure out really right now is when, how much and where. And that’s the confusing part of this whole disease. It’s nothing like we’ve ever seen, nothing like medicine has ever seen,” Dr. Keith Scott said.

Steven Alexander, Molecular and Cellular Physiology professor, is leading the effort to start producing these 3-D printed nasal swabs in large quantities.

“I'm afraid that if these social mitigation factors are released too early that we could be seeing a second peak, which would be a really bad deal,” Ghali told The Ouachita Citizen in an interview.

Multiple wings serving the needs of women and children are being moved from the Ochsner LSU Health Shreveport Medical Center to the St. Mary Medical Center to free up more ICU units to better treat COVID-19 patients.

As part of a national cooperative with the University of South Florida (USF) Health, Northwell Health, New York’s largest healthcare provider, and Formlabs, LSU Health Shreveport has obtained the printing files for a patented swab design, becoming the first in Louisiana to produce these patented 3D-printed swabs.

Dr. Robert Walter, LSUHS lung specialist, said about a week after contracting the virus a patient’s respiratory system begins to weaken. Patients with severe symptoms require a breathing tube and ventilator.

LSU Health Shreveport is bringing testing online that will allow them to check a person’s blood for antibodies that may indicate they are immune to coronavirus.

MyArkLaMiss.com - Scientists at LSU Health Shreveport continue to have a significant impact on the fight against COVID-19 in Louisiana with their latest achievement being able to offer serology testing to support the Convalescent Plasma Therapy clinical trial and help identify ideal plasma donors.

Realizing the need for more testing in rural and other underserved locations in Northwest Louisiana, the Caddo Parish Commission voted to provide up to $175,000 to LSU Health Shreveport for the Clinic’s mobile unit. The allocation will assist with operations and testing. Expanded testing is north Louisiana will occur thanks to a $125,000 gift by Inferno Manufacturing Corporation.

Phase two in the fight against COVID-19 is ramping up. The fight began with testing, now it's the race to find a treatment and eventually a vaccine. Convalescent plasma is so far showing great promise.

LSU Health Shreveport has become one of the leaders in the fight against COVID-19, through its healthcare services, testing and innovative research.The work likely will earn the medical facility a place in the history books as 2020 will undoubtedly be known as the year of the coronavirus. 

Mayor Perkins said, “To combat this virus, we have to put our resources where they are most needed. This partnership between Caddo Parish and LSU Health Shreveport does just that; it provides rapid testing to medically underserved communities in our area.”

To begin opening the state back up, Edwards has said officials need far more diagnostic tests, along with serological tests that could tell whether people have immunity to the virus. 

“We will take their blood and run it through and siphon off the plasma, the plasma will have the antibodies and the antibodies will be administered to critically ill patients,” says LSUHS Chancellor Ghali.

“What we’re so excited about is this, it’s FDA approved. Almost any hospital of any size already has a ventilator, already has the gas and if this is something that does work it could start being applied immediately,” said LSUHS Professor, Keith Scott, MD.

"In general, you have to be symptomatic so the van can go an test them. The test itself is a very short test. I mean, it doesn't take long to do a nose swab. So, you can do an area in a couple of hours," Arnold said. 

Commissioner Jackson said, “This is particularly for individuals who are medically underserved or have access barriers. We want to go off data with the Health Unit to see where there is significant community spread and be aggressive with testing.”

“Louisiana is doing a good job with testing. On a per capita basis Louisiana is number two in the total number of tests done in their state,” said Dr. G. E. Ghali. He says the new numbers show the efforts of the governor are working and if we continue social distancing, the predicted number of deaths will also go down.

It was a battle between the LSUHS medical students and allied health students to see who could rally around their school and community to donate the most units.

For the majority of the first month of the outbreak in the State of Louisiana, Caddo Parish and Shreveport led the way in completed tests. That trend has now been joined by the way that LSU Health Shreveport is attacking the virus in the effort to defeat COVID-19.

It's not a typical blood drive. It’s a battle between the medical students and allied health students to see who can rally around their school and community to donate the most units.

Research from LSU Health Shreveport has shown that nitric oxide is a strong protector against tissue hypoxia. “It’s just really a raging phenomenon that occurs in the lung and if we can just calm that down a little bit and allow the body’s natural systems to come in an heal it, that’s the real goal,” said Scott.

The plasma transfusion is a clinical trial to see whether anitbodies that their immune systems created would help those who are battling a more advanced stage of the coronavirus. The trial is the first of its kind in Louisiana and the third of its kind in the U.S.

The LSU Health Shreveport Department of Medicine has joined up with the Massachusetts General Hospital and the University of Alabama-Birmingham to enlist patients in a test study using inhaled nitric oxide to heal lungs damaged by COVID-19.

Keith Scott, MD, MSc, FCCM, Principal Investigator at LSU Health Shreveport for the nitric oxide clinical trial said, “We have tremendous confidence this therapy will alter the devastating effects of CoVID-19 but we must test it.”

The FDA just released new guidelines allowing us to investigationally use convalescent plasma for patients with moderate to severe COVID-19 infections.  The only source of this convalescent plasma is donations from people that have recovered for at least two weeks from COVID-19 and have produced antibodies. 

Research from LSU Health Shreveport has shown that nitric oxide is a strong protector against tissue hypoxia, which occurs during severe Covid-1 infection”, said Dr. Chris Kevil, Vice Chancellor for Research at LSU Health Shreveport.

Officials say a critically ill COVID-19 patient at Ochsner LSU Health Shreveport Academic Medical Center is being treated with the first convalescent plasma therapy in Louisiana, donated at LifeShare Blood Center just hours before the treatment began Saturday.

Due to some forward thinking by Dr. G.E. Ghali, chancellor of LSU Health Shreveport, three years ago, northwest Louisiana might be in better shape to fight complications from COVID-19 than other areas of the state.

Dr. Martin Sapp, Chair of Microbiology at LSUHS, shares how the EVT Lab will help with current and future viral threats.

Some doctors from LSUHS have made the long haul to the front lines of the COVID-19 fight in Louisiana: New Orleans. Guided by Dr. Angela Cornelius, the seven residents come from various specialties but have the same mission: providing much needed aid to an overwhelmed hospital.

LSU Health Shreveport has sent a medical strike team to assist staff at a hospital in the New Orleans area. The team consists of seven residents and emergency physician Dr. Angela Cornelius. They are currently working at West Jefferson Medical Center in Marrero.

With so many questions surrounding COVID-19, Dr. G. E. Ghali, Chancellor LSU Health Shreveport explains the warning signs. He also discusses ventilators and the race for treatment and a vaccine.

“Certainly we’ve ramped up our testing,” Dr. G.E. Ghali, LSUHS Chancellor, said. “We’ve increased our capacity by 60 percent right off the bat of number of ICU beds that we have.” The increased testing is thanks to the new Emerging Viral Threat Lab that can provide results in less than 48 hours, freeing resources.

The Shreveport Times reached out to Professor Andrew Yurochko, Carroll Feist endowed chair of viral oncology and department vice-chair of microbiology and immunology, LSUHS, with the Emerging Viral Threat lab which began processing COVID-19 samples last Wednesday.

If you are a frontline medical worker in the Shreveport-Bossier area, and could use some additional help, click here to take a survey. Once completed, you’ll be connected with a volunteer who will be able to assist you. You are also able to email olsugroceries@gmail.com with any questions you may have.

Dr. Kevil, in reference to the EVT lab says, "We're ramping up to get to get from about 1,000 to a peak of 2,000 tests a day. Right now we're in the process of working out...a system (between) the clinical laboratory, the hospital and the community so that we can provide the turnaround time of the test of 48 hours, working to get it down to 24 hours."

Chancellor Ghali explains the medical school's growing role in the COVID 19 fight. "We already have a robust and incredibly well known virology department," he says, adding that their experience in SARS virus research laid the groundwork for this challenge. "What (our) lab allows us to do is test up to about 2,000 samples a day." Ghali says these samples are coming to LSUHS from all over the country.

Dr. Puja Nambiar, an infectious disease specialist at LSUHS, states that Shreveport experts have been able to work closely with the team at the Ochsner Health in New Orleans, adopting protocols and surge planning developed by experts a week ahead of the epidemic. Hopefully, that will help stem the tide. (CNN.com)

Working together with Governor John Bel Edwards and following the guidance of state public officials that we improve surge capacity for COVID-19 patients, we are rapidly modifying our St. Mary Medical Center, located in the Highland neighborhood of Shreveport.

As the coronavirus spreads, researchers at academic medical institutions have jumped into the containment battle by developing and deploying tests to detect the virus. They hope to help fill a nationwide shortage of such tests. (AAMC.org)

Forbes.com - Biomedical researchers at Louisiana State University Health Shreveport set up an Emerging Viral threat Lab to process COVID-19 tests with a short turnaround time.

Chancellor G. E. Ghali joins other medical professionals in NW LA to discuss COVID-19 as it relates to our community on KTBS-3 News.

On Wednesday morning, LSU Health Shreveport held a virtual press conference to announce that it has established a COVID-19 testing lab. Officially, the testing lab facility will be known as the Emerging Viral Threat Lab (EVT). 

LSU Health Shreveport has established the Emerging Viral Threat (EVT) Laboratory to address the need for faster detection and processing of COVID-19 tests.

Dr. G. E. Ghali, chancellor of LSUHS, said during a Wednesday press conference that, “Around the 17 of March, I approached the governor and said we have a few road blocks to this and we need your help. Without any questions he jumped right in and created an executive order and by March 25, today, the lab is up and running.”

The EVT Lab is the first in north Louisiana approved by CMS to conduct and analyze tests to determine if an individual has COVID-19.

During a virtual press conference Wednesday morning, Chancellor G. E. Ghali said the facts around Louisiana’s confirmed cases are “really scary” because studies show the state has the fastest growth rate of confirmed cases in the entire world, third in per capita, and the steepness parallels that of Italy and Spain.

Top scientists at LSUHS have created the Emerging Viral Threat Lab in a remarkable amount of time to take on the global pandemic. The (EVT) Lab can initially test 50 samples per day and expects to tests in the hundreds by end of the week and into next week. The test results are determined with 24 to 48 hours. 

Dr. John Vanchiere, an infectious disease specialist at LSU Health Shreveport discusses symptoms and treatment protocol for COVID-19 on KEEL News Radio.

LSU Health Shreveport chancellor, Dr. G.E. Ghali, implores all citizens to adhere to the guidelines set forth by Governor Edwards.

Having an academic medical center is a “gem” touted frequently throughout north Louisiana and beyond. While many in the nation are fearful of having appropriate access to testing and quality care during the Covid-19 pandemic, thanks to LSU Health Shreveport, north Louisiana is infinitely better positioned than most communities to face Covid-19.

Dr. G.E. Ghali, Chancellor of LSU Health Shreveport, anticipates the center will roll out rapid testing for the virus. “We’d be the only place in the state that has the ability of doing in-house testing with a 24 hour turnaround.” 

In this video, Dr. Mark Cogburn, Professor of Clinical Psychiatry and Behavior Medicine, talks to parents about how to talk to their child about COVID-19.

Dr. Yetman says, “We’re very lucky here in Shreveport – we don’t have the population density that other cities have… you can still get out, you can still walk. Exercise both for children and adults is very important for maintaining your physical health as well as your mental health.”